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ABSTRACT
Both clinical and experimental evidence suggest that diabetes
mellitus impairs cardiac performance to a greater extent in the
presence of hypertension than it does in the absence of hypertension.
There is also indirect evidence to suggest that a low thyroid state,
which often coincides with experimental and clinical diabetes, may
contribute to this impairment.

The following study was designed to

characterize selected cardiovascular sequelae of diabetes in the
hypertensive rat, and to determine whether involvement of attendant
hypothyroidism is functionally significant.
study can be summarized as follows:

The hypotheses of this

1) The marked depression in

cardiac performance caused by diabetes in hypertensive rats is
associated with impairments in sarcoplasmic reticular (SR) calcium
uptake and with prolongations in the duration of ventricular muscle
action potentials;

and 2) Demonstrated disturbances in cardiac

performance, SR calcium uptake, and action potential duration caused
by diabetes could then be altered by either thyroid hormone or
insulin treatment in vivo.

To test these hypotheses, spontaneously

hypertensive rats (SHR) were made diabetic with a single injection of
streptozotocin (STZ; 45 mg/kg).

Subgroups of diabetic animals were

treated with either thyroid hormone (T ; 8-10 µg/kg/day) or insulin
3
(10-20 U/kg/day).

After 8 weeks of untreated and treated diabetes,

the following measurements were taken:

1) Indices of performance

(contraction and relaxation) of perfused, working hearts ex vivo;
Rate and extent of calcium uptake by microsomal preparations of
ventricular homogenates in vitro;
of papillary muscle in vitro.

and 3) Action potential profiles

Control groups for various studies

2)

included nonhypertensive Wistar Kyoto (WI<Y) rats, and renovascular
hypertensive (RVH) rats, to rule out strain-dependent effects in the
SHR model, food-restricted nondiabetic rats to control primarily for
reductions in heart size, and rats pretreated with 3-0-methylglucose
to protect against the diabetogenic effects of STZ (as a control for
nonselective STZ-induced cardiotoxicity).

The results showed, first,

that indices of left ventricular (LV) performance ex vivo (e.g., LV
pressure generation and rates of contraction and relaxation) of SHR,
but not WI<Y rats, were depressed by diabetes.

Diabetes-induced LV

mechanical deficits of SHR were ameliorated by either insulin or T
3
treatment.

The adverse effects of diabetes on mechanical function of

SHR hearts were independent of coronary macrolesions, as evidenced by
normal coronary flow rates, myocardial oxygen consumption and
coronary vascular resistance in the diabetic SHR group.

These data

provide additional evidence that a "diabetic cardiomyopathy" at least
partially contributes to depressed function in the SHR and that
thyroid hormone treatment can prevent at least a portion of the
mechanical deficits.

Second, the results showed that diabetes

impaired LV relaxation and depressed rates of SR calcium uptake in
the SHR left ventricle without affecting either measurement in the
WKY group.

Thyroid hormone treatment completely prevented these

mechanical and biochemical changes in the diabetic SHR heart.

The

third component of the results indicated that diabetes prolonged the
ventricular action potential to the same extent in the SHR as it did
in the WKY.

Either insulin or T treatment of diabetic SHR
3

completely prevented the prolongation of the action potential.

As it

did in the SHR strain, diabetes also caused a marked depression in

the performance in hearts of RVH rats.

Similarly, T3 treatment of
diabetic RVH, like T3 treatment of diabetic SHR, prevented the
impairment of cardiac performance.

Collectively, these results

suggest that left ventricular hypertrophy, as a common element of SHR
and RVH models of hypertension, predisposes the myocardium to the
adverse effects of diabetes.

The thyroid hormone deficit associated

with diabetes, in both the SHR and RVH models of hypertension, may
contribute to this myocardial dysfunction.

Furthermore, since

thyroid hormone treatment of diabetic SHR prevents impaired SR
calcium uptake and action potential prolongation, attendant
hypothyroidism may play a significant role in the etiology of
diabetic cardiomyopathy in hypertrophic left ventricle.
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PREFACE
This dissertation was prepared according to the manuscript
thesis plan.

The first section of the dissertation consists of a

general introduction and provides background information, rationale,
hypotheses and specific aims for the following study.
section consists of three manuscripts.

The second

The first two manuscripts are

prepared according to the format of the journal Hypertension.

The

third manuscript is prepared according to the format of the American
Journal Q.f Physiology.

All three papers describe the cardiovascular

effects of either insulin or thyroid hormone treatment in diabetic
genetically hypertensive rats.

The first paper provides detailed

analyses of these effects on ventricular performance of isolated
perfused working hearts.

The second paper focuses specifically on

myocardial relaxation of the working hearts and a biochemical
correlate to this function, Ca
reticulum.

2+

uptake by the sarcoplasmic

The third paper characterizes the effects of diabetes and

thyroid hormone treatment on ventricular action potentials in the
hypertensive rat.
Section three of the dissertation is a general discussion that
encompasses all of the results obtained in each of the three studies
listed above along with data presented in Appendix A.

Appendix A

details the effects of diabetes on cardiac performance in another
experimental model of hypertension, the renovascular hypertensive
rat.

Appendix B provides the computer programs that were developed

and used to acquire the data for most of the analyses.
section is a bibliography for the entire dissertation.
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GENERAL INTRODUCTION
Cardiovascular disease contributes significantly to morbidity
and mortality in the diabetic population (for review see Dillmann
1989).

The incidence of coronary artery disease ·(such as

atherosclerosis) and congestive heart failure (CHF) is 2 - 5 times
greater in the presence of diabetes than it is in the general
population (Kannel et al. 1974).

Cardiac functional abnormalities

that are commonly associated with diabetes include decreases in
ejection fraction and stroke volume and increases in left ventricular
(LV) end diastolic pressure and wall stiffness (Hamby et al. 1974;
Regan et al. 1977).

Impaired diastolic

f~lling

may be the first

clinical sign of diabetes-induced cardiac dysfunction (Park et al.
1988; Ruddy et al. 1988).

In addition to coronary artery disease,

the etiology of CHF in diabetes may also involve either an autonomic
neuropathy or a specific cardiomyopathy or both (Kannel et al. 1974;
Regan et al. 1977; Fisher et al. 1986; Sunni et al. 1986).

Even in

the absence of coronary vascular disorder, the frequency of CHF is
still higher than expected in diabetic patients (Kannel et al. 1974;
Regan et al. 1977).

The term diabetic cardiomyopathy is used to

define depressed heart mechanical performance that results from
myocardial dysfunction independent of the coronary vasculature
(Dhalla et al. 1985; Fein and Sonnenblick 1985; Dillmann 1989).
Diabetic cardiomyopathy may be associated with specific cellular
lesions.

Studies using animals with chemically-induced diabetes

(Penpargkul et al. 1980; Garber and Neely 1983) and animals which are
genetically predisposed to diabetes (Lopaschuk and Tsang 1987; Brady
and Brady 1989; Rodrigues and McNeill 1989) have been useful for
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determining specific areas of cardiomyocyte disruption.

For example,

diabetes promotes an increase in phospholipid incorporation in the
plasma, sarcoplasmic recticular (SR), and mitochondrial membranes
(Gudbjarnason et al. 1987; Lopaschuk and Tsang 1987; Makino et al.
1987; Xiang et al. 1988; Black et al. 1989; Lopaschuk and Spafford
1989).
and Ca

Decreases in specific enzyme activities (e.g., Na+/K+ ATPase
2+

ATPase) and prolonged duration of the action potential (AP)

are often correlated with this altered membrane composition (Fozzard
and Arnsdorf 1986).

These and other cellular changes can interfere

with the heart's normal pump function.

Diabetes depresses indices of

mechanical performance in situ (Regan et al. 1974) and ex vivo
(Penpargkul et al. 1980; Fein et al. 1983; Rodgers 1986).

The

diabetic heart generally exhibits lower ventricular pressure
generation, decreased contractility and prolonged relaxation when
compared to a normal heart (Garber and Neely 1983; Kobayashi and
Neely 1983; Tahiliani and McNeil! 1984; Rodgers 1986).
The risk of cardiovascular complications appears to be greater
when diabetes is combined with hypertension both clinically and
experimentally (Kannel et al. 1974; Factor et al. 1980, 1981; Drury
1985; Fuller 1985; Rodgers 1986; Rodrigues and McNeill 1986; Sparafka
et al. 1988; Bell 1989; Fein et al. 1989; Tzagournis 1989).
Chemically-induced diabetes in hypertensive rats has a more profound
effect on cardiac function than it does in normotensive
(nonhypertensive) models (Fein et al. 1984; Rodgers 1986; Rodrigues
and McNeil! 1986).

For instance, histological and ultrastructural

changes are more evident in the diabetic renovascular hypertensive
(RVH) rat heart than in control rat hearts (Factor et al. 1980, 1981;
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Fein et al. 1989).

Diabetes depresses LV performance to a greater

extent in the spontaneously hypertensive rat (SHR) than in the
normotensive Wistar Kyoto (WKY) or Sprague-Dawley rat (Rodgers 1986).
It may be the presence of preexisting LV hypertrophy, a consequence
of elevated arterial

pressu~e,

that exacerbates the functional

defects in diabetic myocardium (Factor et al. 1983).

Hypertrophic

muscle progresses from an adaptive phase, during which an increase in
muscle mass benefits the heart by redistributing the increase in
workload, to a compromised phase, during which force of contraction
is significantly reduced (Pfeffer et al. 1979; Scheuer and Buttrick
1987).

Even when diabetes is induced in animals whose cardiac

function is still well within the adaptive phase of hypertrophy,
cardiac function subsequently is more severely impaired than it is in
nonhypertrophic muscle (Rodgers 1986; Rodrigues and McNeill 1986).
Since diabetes depresses systolic arterial pressure and can reverse
LV hypertrophy in SHR (Rodgers 1986), neither sustained hypertension
nor LV hypertrophy is required in order to manifest these
cardiodepressive effects.

Thus, LV hypertrophy may predispose the

heart to the adverse effects of diabetes.
Hypothyroidism, or a "low thyroid state", is often reported as a
secondary metabolic disorder of diabetes (Pittman et al. 1979; Bagchi
1982; Dillmann 1989), and insulin replacement therapy has been shown
to restore normal thyroid status in diabetic rats (Garber et al.
1983).

Hypothyroidism and diabetes have a number of similar effects

on cardiac metabolism and function.

For example, both pathological

conditions impair myocardial contractility, depress myosin ATPase
activity and SR ca 2+ uptake (Suko 1973; Takacs et al. 1982; Morkin et
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al. 1983; Dhalla et al. 1985; Rodgers et al. 1986), prolong the
cardiac AP (Freedberg et al. 1970; Nordin et al. 1985; Sauviat and
Feuvray 1986; Capasso et al. 1986; Binah et al. 1987) and reduce
sensitivity to adrenergic agonists (Bilezikian and Loeb 1983;
Gotzsche 1986).

Whether the cardiovascular effects of diabetes are

at least in part due to the attendant hypothyroid state has been
addressed in a number of studies (Tahiliani and McNeil! 1986).
Thyroid hormone replacement therapy in normotensive diabetic rats has
been shown to be either ineffective (Tahiliani and McNeil! 1984;
Tahiliani and McNeill 1985; Barbee et al. 1988) or only partially
effective (Garber et al. 1983; Goyal et al. 1987) in restoring
cardiac function and atrial AP configuration (LeGaye et al. 1988).
The prevailing view up to now is that the attendant hypothyroidism
does not play a significant role in diabetic cardiomyopathy in the
absence of hypertension (Tahiliani and McNeil! 1986; Dillmann 1989).
Indirect evidence, however, suggests that the influence of an
imbalance in thyroid status on the cardiovascular system may have a
greater impact in the diabetic SHR than it does in diabetic
normotensive strains.

Thyroidectomy (Tx) of young SHR prevents the

onset of elevated systolic arterial pressure (Rioux and Berkowitz
1977), and either Tx or methimazole treatment of SHR decreases
contractility and pressure generation of the isolated working heart
(Rodgers 1986; Rodgers and McNeil! 1986).

These effects of

hypothyroidism in the SHR strain are reminiscent of, but less
pronounced than, those of diabetes (Rodgers 1986).
A common manifestation of diabetes and hypothyroidism is reduced
rate of Ca 2+ uptake by the SR (Suko, 1973; Penpargkul, 1981).
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This

biochemical impairment is closely associated with depressed rates of
myocardial relaxation in both diabetes (Penpargkul et al. 1980;
Penpargkul et al. 1981) and hypothyroidism (Rodgers and McNeill
1986).

Load-dependent relaxation of cardiac muscle is dependent upon

the activity of SR in order to lower intracellular free ca 2+
concentrations (Brutsaert et al . 1980; Bers 1987).

The adverse

effects of diabetes on indices of relaxation do not appear to be
dependent on thyroid state in nonhypertrophic muscle (Tahiliani and
HcNeill 1984).

While the effects of LV hypertrophy on SR ca 2 + uptake

and relaxation of heart muscle are not consistent (Limas and Cohn
1977; Capasso et al. 1986; Rodgers et al. 1986; Cuneo and Grassi de
Gende 1988), the combined effects of diabetes and LV hypertrophy are
more pronounced on isometric relaxation of RVH rat papillary muscle
(Fein et al. 1984).

The interaction of diabetes and LV hypertrophy

myocardial relaxation and SR ca 2 + uptake have not been investigated.
The cardiac AP configuration is similarly altered by the effects
of either diabetes or hypothyroidism (Aronson and Keung 1983; Fein et
al. 1983; Nordin et al. 1985; Capasso et al. 1986; Capasso et al.
1986; Sauviat and Feuvray 1986).

Prolongation of the cardiac AP is

the most consistent consequence common to these abnormalities, and
may be functionally related to associated mechanical alterations
which are also characteristic of each condition.

The presence of

hypertrophy alone is not always associated with changes in AP
configuration.

The etiology and duration of the hypertrophy may

influence the extent of the electrophysiological changes.

Neither

right ventricular hypertrophy in cat (Kaufmann et al. 1971) nor
papillary muscle hypertrophy in SHR (Volkmann et al. 1989)
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significantly prolong the cardiac AP when compared to nonhypertrophic
controls.

However, the hypertrophy of RVH papillary muscle prolongs

AP duration (Aronson 1980) and this increase is magnified in a time
dependent manner (Capasso et al. 1986).

A combin'a tion of any of

these disease states (diabetes, hypothyroidism or hypertrophy) may
have additive effects on ventricular transmembrane potentials (Fein
et al. 1984; LeGaye et al. 1988), as they seem to have on mechanical
function (Fein et al. 1984; Rodgers 1986; Rodrigues and HcNeill
1986).
Ventricular muscle contraction begins with the depolarization of
the sarcolemma.

The influx of calcium ions during the AP appears to

trigger the release of additional ca 2+ from the SR, raising
intracellular free ca 2+ levels and promoting contraction (Fabiato and
Fabiato 1979).

Changes in membrane potential properties can

therefore alter mechanical activities.

Too much or too little

intracellular free ca 2+ is detrimental to cell function (Dhalla et al
1985; Morad and Cleemann 1987).

The accumulative effects of

prolonged AP duration and lower rates of Ca

2+

uptake may be to

increase intracellular free ca 2+ concentrations, reduce ca 2+
dissociation from the contractile filaments, and lead to depressed
rates of myocardial relaxation.

The interaction of these and other

cellular events provide the basis for the experimental design of the
following studies.
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The working hypotheses of this study, and their rationales, are
listed below.

1) Thyroid hormone treatment of diabetic SHR will at least partially
prevent the decline in cardiac performance affected by chronic
(8 weeks) diabetes mellitus.

Depressed cardiac function in

thyroidectomized SHR is similar to, but not as severe as in
diabetic SHR (Rodgers 1986; Rodgers and McNeill 1986).
Furthermore, thyroidectomy as well as diabetes depresses
systolic arterial pressure in SHR (Rioux and Berkowitz 1977;
Rodgers 1986).

The cardiodepressive effects of diabetes in SHR

may in part be influenced by a low thyroid state.
2) Chronic diabetes should impose a more pronounced impairment in the
rate and extent of LV relaxation and SR Ca

2+

uptake in the SHR

than it will in nonhypertrophic, nonhypertensive rats.

A common

physiological consequence of either hypertrophy or diabetes is
impaired myocardial relaxation (Fein et al. 1980; Penpargkul et
al. 1980; Capasso et al. 1986).

The combination of diabetes and

hypertrophy has a greater detrimental effect on myocardial
relaxation than does either disease state alone (Fein et al.
1984; Rodrigues and McNeill 1986).
depressed rates of SR Ca

2+

Some studies have reported

uptake in both hypertrophic and

diabetic heart muscle (Limas and Cohn 1977; Penpargkul et al.
1981).

The adverse effects of diabetes on LV relaxation and SR

Ca 2+ uptake may be greater in hypertrophic than in
nonhypertrophic myocardium.
3) Thyroid hormone treatment of diabetic SHR will at least partially
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prevent the decline in LV relaxation and SR Ca 2+ uptake affected
by chronic diabetes mellitus.

Like diabetes, hypothyroidism i s

associated with impaired myocardial relaxation and depressed
2
rates of ca + sequestration by the SR (Suko 1973; Penpargkul et
al. 1980; Penpargkul et al. 1981; Takacs et al. 1982; Rohrer and
Dillmann 1988).

The hypothyroidism that attends diabetes may

influence indices of myocardial relaxation in SHR.
4) Chronic diabetes will prolong the ventricular AP to a greater
extent in SHR than in nonhypertrophic, nonhypertensive rats.

A

common electrophysiological effect of diabetes and some models
of hypertrophy is the prolongation of the cardiac AP (Gulch et
al . 1979; Aronson and Keung 1983; Fein et al. 1983;

Nordin et

al. 1985; Thollon et al. 1985; Sauviat and Feuvray 1986;
Volkmann et al. 1989).

Diabetes exacerbates the prolonged AP in

the hypertrophic RVH ventricular AP (Aronson 1980; Fein et al.
1984).

Diabetes may have a more pronounced effect on AP

duration in SHR papillary muscle when compared to WKY muscle .
. 5) Thyroid hormone treatment of diabetic SHR will at least
partially prevent the diabetes-induced prolongation of the
ventricular AP.

Either diabetes or hypothyroidism alone,

prolongs the ventricular AP in nonhypertensive rats (Capasso et
al. 1986; Sauviat and Feuvray 1986).

Thyroid hormone treatment

prevents some of the AP configurational changes of atrial muscle
in diabetic rats (LeGaye et al. 1988).
6) Chronic diabetes will depress LV performance in isolated RVH rat
hearts to a greater extent than in hearts from normotensive
rats.

LV function is profoundly depressed in isolated working
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hearts of diabetic SHR (Rodgers 1986; Rodrigues and McNeill
1986) .

Diabetes may impair isometric relaxation in RVH

papillary muscles more so than i n nonhypertensive,
nonhypertrophic muscles (Fein et al. 1983; Fein et al. 1984).
Hypertrophy, regardless of the etiology, may predispose the
myocardium to the adverse mechanical effects of diabetes.
7)

Thyroid hormone treatment of RVH rats will at least partially
prevent the cardiodepressive effects of diabetes.

This last

study will be conducted primarily to ascertain whether the
cardiac impairments seen in the diabetic SHR isolated heart and
the effectiveness of T treatment on heart performance, is
3
independent of the etiology of hypertension in the rat.
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The specific aims of the study are as follows:

1) LV performance of SHR will be evaluated using an isolated perfused
working heart preparation (Rodgers 1986).

Diabetes will be

chemically induced and certain animals will be chronically
treated with either insulin or thyroid (T ) hormone. Various
3
other control groups will be included in order to identify
contributing factors that may be secondary to diabetes.

For

example, to assess the cardiovascular effects of malnutrition
and non-specific effects of the diabetogenic agent
streptozotocin, food restriction and pretreatment with
3-0-methylglucose (Ramanadham et al. 1987) will be employed,
respectively.

T -treated nondiabetic SHR will also be included.
3
2) A detailed examination of ventricular relaxation and a biochemical
correlate, SR Ca 2+ uptake by isolated LV microsomes, will be
analyzed in both SHR and normotensive WKY.

These indices of

relaxation will be evaluated in hearts from diabetic and
nondiabetic animals with or without insulin or T3 treatment.
3) Resting membrane potential and AP will be recorded from papillary
muscle fibers of normal and diabetic SHR and WKY, and insulinor T - treated diabetic SHR.
3
4) The effects of diabetes and hormone treatment upon cardiac
performance will be assessed in isolated working hearts of RVH
rats.

Control groups similar to those described for the SHR

study (11 above) will be included.
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Insulin, Thyroid Hormone and Heart Function
of Diabetic Spontaneously

-11-

Hyp~rtensive

Rat

SUMMARY
Diabetes impairs cardiac performance more extensively in
hypertensive rats than it does in nonhypertensive strains.

A "low

thyroid state" may contribute to the adverse cardiovascular effects
of diabetes in the spontaneously hypertensive rat (SHR).

We tested

this hypothesis by comparing the effects of thyroid hormone with
those of insulin treatment on cardiac performance of diabetic SHR.
Diabetes was induced with streptozotocin (45 mg/kg).

Subsets of

diabetic animals were treated with either insulin (10-20 U/kg/day) or
triiodothyronine (8-10 µg/kg/day).

Heart rate and systolic arterial

pressure were obtained at weekly intervals.

After eight weeks,

cardiac function was assessed using an isolated working heart
preparation.

Diabetes reduced arterial pressure and heart rate in

vivo, and markedly depressed cardiac performance under volume and
pressure loading conditions ex vivo, confirming previous
observations.

As

expected, insulin treatment prevented the

bradycardia and depressor effect in vivo, and the impairment of
cardiac performance ex vivo caused by diabetes.

The triiodothyronine

treatment duplicated the effects of insulin on the hemodynamic
measurements in vivo, and corrected nearly all depressed indices of
performance of diabetic SHR hearts ex vivo.

Both treatment regimes

successfully reduced eight-week mortality when compared with the
untreated diabetic group.

The results support the hypothesis that a

low thyroid state may contribute to the cardiovascular dysfunction in
diabetic SHR.

Left ventricular hypertrophy may be an important

factor in this phenomenon.
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INTRODUCTION
Diabetes mellitus is associated with cardiac impairments in
humans

1

and in experimental animals 213

Both clinical and

experimental "diabetic cardiomyopathy" may be exacerbated by
hypertension

4

Chemically induced diabetes in hypertensive rats has

a more profound effect on cardiac function than it does in
normotensive models 5- 7 .

Collectively, the data suggest that pressure

load-induced left ventricular hypertrophy increases the
susceptibility of the myocardium to diabetes related derangements 1-7
Hypothyroidism, or a "low thyroid state", is often reported as a
8

secondary metabolic disorder of diabetes , and insulin replacement
therapy has been shown to restore normal thyroid status in diabetic
9

rats .

Hypothyroidism and diabetes have a number of similar effects

on cardiac metabolism and function.

For example, both pathological

conditions impair myocardial contractility, depress myosin ATPase
. re t•icu 1ar Ca 2 + up t a ke 10 - 12 , an d re d uce
. •t y an d sarcop 1asm1c
ac t iv1

sensitivity to adrenergic agonists 13

Whether the cardiovascular

effects of diabetes are at least in part due to the attendant low
thyroid state has been addressed in a number of studies.

Thyroid

hormone treatment of normotensive diabetic rats has been shown to be
. ff ec t•ive 14115 or on 1y par t•ia 11 y e ff ec t•ive 9 in
.
. res t or1ng
e1"th er ine
cardiac function.
Indirect evidence suggests that the influence of an imbalance in
thyroid status on the cardiovascular system may have a greater impact
in the diabetic spontaneously hypertensive rat (SHR) than it does in
diabetic normotensive strains.

Thyroidectomy (Tx) of SHR prevents

.
the onset of elevated systolic arterial
pressure (SAP) 16 ' 17 , and

-13-

either Tx or methimazole treatment decreases contractility and
pressure generation of the isolated working heart 6117

These effects

of hypothyroidism in the SHR strain are reminiscent of, but less
pronounced than, those of diabetes 6
The following investigation was designed to assess the impact of
the attendant hypothyroidism on cardiac function in the diabetic SHR
by comparing the effects of triiodothyronine (T ) treatment with
3
those of insulin therapy.

The results add support to the hypothesis

that attendant hypothyroidism contributes to the adverse cardiac
effects of diabetes in the SHR.
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METHODS
Animal Groups .

Male SHR were obtained from Charles River Breeding

Laboratories (Wilmington, MA), housed communally and fed ad libitum
unless otherwise indicated .

At 15 weeks of age animals were weight

matched and earmarked for either nondiabetic or diabetic groups.
Diabetes was induced with a single tail vein injection of
streptozotocin (STZ), 45 mg/kg bw (Sigma Chemical Co., St. Louis, MO)
after animals were lightly etherized.

The STZ was dissolved in

citrate buffer (0.1 Hat pH 4.5) just prior to use.

A subset of

animals was first injected with 3-0-methylglucose (OMG; 1.2 mmol/150
g BW), followed by STZ within one minute 18 .

Animals in the

nondiabetic groups were also etherized and given similar volumes of
the citrate buffer alone.

Urine glucose levels were estimated using

DIASTIX(R) (Ames, Elkhart, IN).
animals that received STZ.

Diabetes was confirmed in all

No urinary glucose was detected in the

OMG group.
The following treatment regimes were begun three days after the
tail vein injections.

Diabetic animals were further divided into

four subgroups and were treated with one of the following:
insulin (LI; Sigma), 20 U/kg/day s.c.;

protamine zinc insulin (PZI;

Eli Lilly Co., Indianapolis, IN), 10 U/kg/day s.c.;
8-10 ug/kg/day s.c.

Lente

or T3 (Sigma),

The fourth group of diabetic animals remained

untreated for the duration of the experiment.

A preliminary study

was conducted in order to determine an appropriate T3 dose in
15
diabetic SHR 19 . An initial T dose of 30 µg/kg/day
resulted in
3
elevated systolic arterial pressure and heart rate compared to
untreated nondiabetic animals.

The T dose was subsequently reduced
3
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to 10 µg/kg/day and readjusted to 8 µg/kg/day after 6 weeks so that
heart rates of the treated, diabetic animals matched those of the
nondiabetic controls (see Figure lB).
also subdivided:
µg/kg/day s.c.

The nondiabetic animals were

untreated; food restricted (FR)j or T , 8-10
3
The FR animals were housed individually, and their

food allowance was adjusted so that their weights were similar to
those of the untreated diabetic group.
In Vivo Measurements.

Weekly measurements of SAP, heart rate (HR)

and body weight (BW) were taken just prior to the tail vein
injections and then for eight subsequent weeks.

SAP and HR were

obtained in triplicate using standard tail-cuff sphygmomanometry,
after the animals were placed in a temperature controlled chamber
(34°C) for 10-15 minutes.
the daily injections of r

These measurements were recorded before
3

or insulin, and after the food restricted

group was fed.
Serum Assays.

The animals were killed by rapid decapitation eight

weeks after the STZ or citrate buffer injections.

The serum samples

were collected 15-18 hours subsequent to the final insulin or T
3
injection, and stored at -2ooc for future determinations.

The degree

of diabetes was assessed by serum glucose values using a glucose
oxidase assay (Sigma).

Animals were considered diabetic if serum

glucose concentrations exceeded 300 mg/dL.

Serum immunoreactive

insulin activity, total T and total thyroxine (T 4 l were determined
3
by radioimmunoassay (Cambridge Medical Diagnostics, Billerica, MA).
Serum levels of insulin were quantified using rat insulin (generously
provided by Dr. R. Chance of Eli Lilly, Inc.) as a standard.
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Cardiac Performance.
described previously

The hearts were quickly removed and perfused as
6

In brief, the perfusion apparatus was

designed to allow manipulations in both volume loading (left atrial
filling pressure, LAFP) and pressure loading (resistance to aortic
ejection).

Left ventricular pressure (LVP) and aortic pressure (AP)

were monitored continually through indwelling cannulae coupled to
pulse transducers (Stratham, Hato Rey, PR).

Aortic flow rate (AFR)

and coronary flow rate (CFR) were quantified intermittently.
Myocardial oxygen consumption (V0 l was assessed with an in-line
2

o2

electrode (Transidyne Corp., Ann Arbor, HI) confluent with the
coronary perfusate (see calculations below).
Hearts were perfused with nonrecirculating Krebs-Henseleit
buffer maintained at 37oc.

The buffer contained 120 mH NaCl, 5.6 mH

KCl, 0.65 mH MgS0 , 1.21 mH NaH Po , 25 mH NaHC0 , 2.4 mH CaC1 , 0.2
4
2 4
3
2
mH EDTA and 10 mH glucose (pH 7.4 when gassed with 95\ o and 5%
2
co 2J. Bipolar electrodes (attached to a Grass SD9 Stimulator; Grass
Instruments, Quincy, MA) were placed on the right atrium, and hearts
were paced at 300 beats per minute.

Occasionally, endogenous

rhythmicity exceeded 300 bpm at which time external pacing was
discontinued.

The data were continually recorded on a chart recorder

(Narco Trace Hodel 80;

Narco Biosystems, Houston, TX) and a

dedicated computer (Buxco Corp., Sharon, CT).

LVP waves were also

recorded and stored in an IBM PCII using ASYST(R) software (Macmillan
Software Co., New York, NY) and A/D conversion hardware (Data
Translation Inc., Marlborough, MA).

To ensure the stability of each

preparation, LVP generation was monitored prior to data collection
for 10-15 minutes while LAFP was set at 15 cm H o and resistance to
2
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aortic ejection was set at 1.54 kPa/cm 3 .min- 1 .

Measurements were

first recorded during volume loading at LAFPs of 5, 10, 15, and 20 cm
H o while holding resistance constant at 1.54 kPa/cm 3 .min- 1 .
2

They

were then recorded during pressure loading at aortic resistances of
0.19, 0.41, 1.54 and 3.13 kPa/cm 3 .min-l while holding LAFP at 15 cm
H o.
2

Total perfusion time rarely exceeded 30 minutes.

Heart Weight Ratios.

Once the data were collected, the hearts were

removed from the perfusion apparatus and blotted dry.

The aorta was

removed, and the following wet weights were obtained;

whole heart

(HW), left ventricular (LV) including the septum, and right
ventricular (RV).

These weights were used to assess the degree of

left ventricular hypertrophy 6
Calculations.

Direct measurements included LVP, left ventricular

end-diastolic pressure (EDP), AFR, CFR, aortic pressures (including
mean aortic pressure (MAP)), and po

2

of the coronary effluent.

Indices of heart performance included left ventricular pulse pressure
(LVPP as maximum LVP minus EDP), maximum rate of left ventricular
pressure generation (LV + dP/dt), hydraulic power (power as the
product of LVPP and cardiac output (CO=AFR plus CFRJ per gram HW) and
stroke work (SW as the ratio of power to HR).

Myocardial oxygen

consumption (V0 2 ) was calculated as the product of oxygen extracted
from the buffer, CFR and oxygen solubility in buffer at 37°c (31.25
µL/cm 3 ) and normalized for HW.

The efficiency of contraction (E) was

then calculated as the ratio of power to vo .
2

Coronary vascular

resistance (CVR) was estimated from the slope of the regression line
6
when MAP was plotted against CFR at the four pressure loads .
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Statistical Analyses.

The differential effects of diabetes and the

hormone treatments were evaluated by analysis of variance (with
repeated measures where appropriate), and the Student Newman-Keuls
test for multiple comparisons (Statistical Analysis System, Cary,
NC).

Group means were considered statistically different ·from each

other if the probability value was less than 0.05.
probabilities were not reported.
statistically;

Lower

All group comparisons were made

however, in most cases it was only necessary to

present comparisons of each experimental group to the untreated,
nondiabetic SHR.

Additional comparisons, between experimental

groups, were noted only if they had obvious relevance to the
discussion.
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RESULTS
Serum Assays.

Serum glucose levels were elevated in all STZ-injected

groups except those which had been pretreated with OHG (Table 1).
Treatment with PZI controlled the hyperglycemia more effectively than
LI did, but neither treatment restored serum glucose levels to that
of the nondiabetic animals.

Glucose levels of the FR and T -treated
3

nondiabetic SHR were not different from those of the untreated,
nondiabetic group.
Hypoinsulinemia was evident in both the untreated and the
T -treated diabetic rats.
3

Both PZI and LI treatments markedly

elevated serum immunoreactive insulin activity; PZI effected the most
pronounced increase.

The elevated levels may reflect a

subsensitivity to exogenous insulin in the diabetic rat.

The serum

insulin levels of all the other groups were normal.
Diabetes also reduced serum T and T levels.
3
4

Either insulin or

T treatment prevented the decline in T concentration.
3
3
treatment also reversed the drop in T levels.
4

Insulin

However, T treatment
3

of either diabetic or nondiabetic SHR markedly suppressed serum T
4
concentrations.

The OMG and FR groups had normal T values but the
3

FR group had slightly depressed T levels.
4
Body and Heart Weights.
of SHR (Table 2).

Diabetes reduced both heart and body weights

Treatment with PZI completely prevented these

changes, whereas LI was only partially effective.

In contrast, T3

therapy did not affect the decline in HW, but increased the extent of
the loss in BW, of diabetic SHR.
SHR had no effect on BW or HW.

Administration of T to nondiabetic
3
The effects of STZ-induced diabetes
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on BW and HW were nearly duplicated by food restriction, and
completely blocked by OMG pretreatment.
The ratios HW/BW and LV/BW, which are indices of relative
cardiac hypertrophy, and LV/RV, which is an index of absolute left
ventricular hypertrophy 6 , were not significantly affected by any of
the experimental manipulations except one;

the extent of relative

hypertrophy was increased in the T -treated diabetic group.
3
Mortality.

The mortality rate of the diabetic SHR was about 64%,

which was much higher than that of any other group (Table 3).

As

expected, insulin treatment (either PZI or LI) prevented the eight
week mortality of diabetic SHR.

Unexpectedly, T treatment was as
3

effective as insulin was in preventing (or delaying) mortality of the
diabetic animals.

The mortality in the FR group occurred early in

the study, as a result of attempts to exactly duplicate the mean BW
of the diabetic group.

Slight upward adjustments of the food

allotment prevented further mortality, and resulted in mean BW which
was slightly higher than that of the diabetic group by the end of the
eight week period (see Table 2).

The mortality of diabetic SHR was

completely prevented by treatment with OMG prior to STZ injection.
Systolic Arterial Pressure and Heart Rate.

Diabetes depressed SAP of

SHR in. vivo, beginning about four weeks after STZ injection (Figure
lA), confirming previous results 6
decline in HR (Figure 18).

It also caused a progressive

Either insulin (PZI or LI) or T3

treatment prevented both the depressor and bradycardic effects of
diabetes.

Since both PZI and LI restored SAP and HR to control

values, the two insulin-treated groups were pooled in Figure 1 and
Table 4.

A summary of the SAP and HR measurements in the remaining
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control groups at the eight week time point is provided in Table 4.
With one exception, none of these values is significantly different
from that of the untreated, nondiabetic group.

Only the HR of the FR

group was significantly depressed.
Cardiac Performance Ex Vivo.

Diabetes impaired the performance of

SHR hearts ex vivo, under either volume- or pressure-loading
conditions (Figures 2 and 3).

The impairment was evident as a

decline in LVPP and SW at higher volume loads (Figure 2), and in LVPP
at higher pressure loads (Figure 3).

Diabetes also depressed left

ventricular contractility (LV + dP/dt; Table 5).

These results

generally confirm those of previous reports 617 , which had also
demonstrated that the magnitude of the cardiac impairment due to
diabetes is greater in the SHR than it is in normotensive rats.

Both

insulin treatments of diabetic SHR (either PZI or LI) completely
prevented the decline in cardiac performance;

in the interest of

clarity, therefore, the data for the two insulin-treated groups were
pooled in Figures 2 and 3 and in Tables 5-7.

Treatment of diabetic

SHR with T was nearly as effective as was insulin therapy (Figure
3
4); it completely prevented all effects of diabetes except that it
only partially maintained LVPP at the highest volume load (Figure 2A
and Table 5) and depressed LVPP at the lowest pressure load (Figure
3A).

In addition, T treatment of diabetic animals significantly
3
increased SW at a LVFP of 10 cm H2o (Figure 28). Neither LVPP, SW,
nor contractility of any of the other control groups was different
from the corresponding value of the nondiabetic control under either
volume-loading (Table 5) or pressure-loading conditions (data not
shown).

Thus, neither malnutrition nor direct cardiotoxic effects of
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STZ appear to contribute significantly to the cardiac impairments of
the diabetic SHR.
Diabetes had no effect on
efficiency of contraction (E;

vo 2 , co,

hydraulic power, or

Table 6).

None of the experimental

groups differed significantly from the control with regard to any of
these variables, except that the CO (per gram HW) of the T3-treated
diabetic group was elevated.

This was related more to the reduction

in heart size than it was to any increase in total output

20

Although diabetes reduced total coronary flow rate (CFR), it had
no effect on either CFR per gram HW or on CVR (Table 7).

Thus, the

impaired LVPP, SW and contractility of diabetic SHR hearts were not
associated with restricted coronary flow.
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DISCUSSION
Recent results from this laboratory suggested that a low thyro i d
state might contribute significantly to changes in cardiac
performance of diabetic SHR 6117 . Accordingly, we expected that T

3

treatment of diabetic SHR might reduce the magnitude of the
subsequent impairment in mechanical function.

We were somewhat

surprised, though, that the dose of T used in this study was almost
3
as effective as insulin was in preventing the depressions in
measurements of heart function, including pressure generation, rates
of contraction, and stroke work.
Our results obtained from SHR differ from previous reports of
the effects of T treatment on cardiac function and hemodynamic
3
.
d.
.
measuremen t s in ia be t·ic normo t ens1ve
ra t s 9,14,15 . In the earlier
studies, T treatment - at doses ranging from approximately 8 to 30
3
µg/kg/day - was either ineffective or partially effective in
preventing diabetes-induced myocardial functional impairments.

For

the present study, we selected the dose of T according to its
3
ability to maintain normal HR in vivo, an index which is a sensitive
indirect indicator of thyroid status.

This turned out to be about

2-3 fold greater than "physiologic" replacement doses in
nonhypertensive rat strains

21

.

The T dose used herein did not
3

appear, however, to impose a hyperthyroid condition in diabetic SHR
for several reasons:

1)

It did not elevate serum T levels above
3

normal, when measured at the same time point after injection, in
either the diabetic or the nondiabetic SHR groups (Table l); 2) The
same dose given to nondiabetic SHR (Table 4) or to diabetic SD rats
had no effect on SAP or HR in vivo; and 3) T3 treatment of
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nondiabetic SHR had no effect on any of the indices of cardiac
performance ex vivo (Tables 5- 7).

Although T treatment reduced body
3
weights of the diabetic SHR, it had no effect on this measurement in
the nondiabetic control group (Table 2) .

It may not be appropriate

to assume that doses of T which are adequate for therapy of simple
3
hypothyroidism should be enough to correct the hypothyroid state
induced by diabetes.

Diabetic hypothyroidism in the rat is

characterized not only by low serum hormone levels, but also by
target tissue resistance.

For example, diabetes impairs peripheral

T4 to T conversion, tissue T uptake, and both affinity and density
3
3
23124
of nuclear T receptors
3
The differences in the effects of T treatment between the SHR
3
and normotensive diabetic rats are probably related to the elevated
arterial pressure of SHR, and not to differences related specifically
to the genetic strain.

We have preliminary results (unpublished

observations) that T is as effective in the diabetic renovascular
3
hypertensive (RVH) rat as it is in the diabetic SHR. A common
feature of the two models, left ventricular hypertrophy (LVH), may
increase cardiac susceptibility to a number of stresses including
·
db y d.ia be t es 41617 , hypo th yro1·d·ism12 , or isc
· haem1a
· 25
th ose impose
Our results suggest that the hypothyroidism accompanying diabetes has
a more profound cardiovascular effect in animals with elevated
arterial pressure, and that hypertrophied myocardium may be
functionally more dependent upon thyroid status than is
nonhypertrophic heart muscle.

This hypothesis is supported by the

observation that thyroidectomy reduces left ventricular contractility
17
to a greater extent in the SHR than it does in the WKY .
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There are a number of mechanisms by which T treatment might
3
effectively reverse the cardiac functional impairments of diabetes,
especially of hypertrophic heart muscle.

A common manifestation of

diabetes, hypertrophy and hypothyroidism on rat ventricular muscle is
a shift from the predominant v

1

isozyme 9111121126 -

28

to the v myosin
3

The effects of hypertension and diabetes (with

or without hypothyroidism) on myosin isozyme profiles may thus be
additive, but this hypothesis has not been tested.

T treatment of
3

the diabetic SHR may change the ratio of myosin isozyme activity in
favor of v

1

and this may in turn help to explain the increased left

ventricular contractility in this group (Table 5).

Another

biochemical change frequently observed in hearts from either
diabetic, hypertensive or hypothyroid animals is depressed
sarcoplasmic reticular (SR) ca 2+ uptake, which correlates with
.
. d myocar d"ia 1 con t rac t·ion an d re 1axa t ion
· io,12,2a
impa1re

Although

2
thyroid hormone treatment did not restore SR ca + uptake of diabetic
normotensive rats 15129 , its effectiveness on diabetic hypertensive
muscle has recently been demonstrated (see accompanying manuscript).
Metabolic derangements in the diabetic heart include decreased
glucose utilization and increased lipid accumulation

30

These in

turn have been linked to changes in energy substrate availability and
membrane integrity and function in the heart 10
exacerbate these metabolic effects.

Hypertrophy may

Increased vulnerability of

hypertrophic myocardium to metabolic stress may be related either to
a lower energy state
SHR 7132 - 34 •

31

or to abnormal lipid metabolism in the

Interestingly, the vasodilator hydralazine reduced serum

lipids and improved cardiac function but also corrected the attendant
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hypothyroid state in diabetic nonhypertensive rats 35 .

Thyroid

hormone may relieve some of these stresses in diabetic SHR, perhaps
by i ncreasing the utilization of fatty acid by the myocardium 36 , by
stimulating glucose uptake and utilization

37

, or by augmentating

l'in secre t ion
' 38 , a 1th oug h our d a t a (T a bl e 1) di'd
. d uce d insu
.
g 1ucose-1n
not support the latter possibility.

Thyroid hormone may also enhance

the responsiveness of the myocardium to sympathoadrenal influences
(see below) .
Several alternative interpretations of our results could be
eliminated by the control studies.

Amelioration of the

cardiodepression and mortality by either insulin or T treatment, and
3
18
by pretreatment with the glucose analog OMG , ruled out the
possibility that direct cardiotoxicity of STZ contributed to the
morbidity and mortality of diabetes.

Complete glycemic control was

not necessary for preservation of cardiac functional activity,
supporting previous · observations 34139 , both PZI and LI maintained
pump function without normalizing serum glucose values (Table 1) .
Malnutrition alone could not account for the observed
cardiodepressive effects of diabetes in our study, since performance
was not impaired in the food restricted group (Tables 5 and 6; see
also references 3 and 6).
Hypothyroidism probably also contributes to the reduction in SAP
in vivo of diabetic SHR 6 (Table 4).

Thyroidectomy prevents the

development of hypertension in this mode1 16117 , whereas T treatment
3
of diabetic SHR prevents the decline in SAP (Table 4).

The latter

result also illustrates that the restorative effects of r

3

(and

insulin) treatment are manifest in the face of sustained elevations
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in arterial pressure load.

The depressor effect of diabetes in SHR

likely involves both vascular and cardiac components.

Yamamoto and

Nakai 40 seemed to show in their Table 3 that moderate diabetes
reduced total peripheral resistance of SHR by about 10-20%, depending
on the duration of diabetes .
in the diabetic SHR.

Administration of T may increase TPR
3

On the other hand, variations in SAP of either

diabetic or hypothyroid SHR, whether treated or untreated, always
seem to be associated with parallel changes in cardiac
6 7 17
performance ' '
(Table 4 and 5).

Tsujimoto and Hashimoto

41

attributed most of the rise in SAP of T -induced hyperthyroid rats to
3
cardiac, rather than to vascular, effects of T .
3
Treatment with T , like insulin, also corrected the bradycardia
3
of diabetic SHR (Figure 18).

The bradycardia associated with either

diabetes or hypothyroidism has been attributed, at least in part, to
. 1 responsiveness
.
t o a d renerg1c
. s t"imu 1a t•ion 13142
d epresse d myocar d ia
Both hypertrophic 43 and diabetic

44

myocardium have been shown to

possess a lower density of functional a-adrenoceptors, and both
insulin and T3 may be involved in the regulation of cardiac
8-adrenoceptor density.

Insulin may act indirectly by restoring

serum T levels. Depressed myocardial B-adrenoceptor numbers of
3
diabetic SD rats were restored to normal with either insulin or T4
treatment, while those of thyroidectomized diabetic rats were not
affected by insulin treatment alone 45 .

The chronotropic action of T

in vivo may also involve a direct effect of the hormone on pacemaker
cells 46 •

The available evidence implies that at least a significant

portion of the bradycardia of experimental diabetes, in the presence
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3

or absence of hypertension, can be attributed to the attendant
hypothyroidism.
In conclusion, the cardiac impairments associated with diabetes
in the SHR can be prevented by either insulin or T treatment. To
3
our knowledge this is the first account of a moderate dose of T
3
successfully restoring cardiac performance in experimental diabetes.
In addition, T treatment, like insulin, prevented the fall in
3
arterial pressure and bradycardia induced by diabetes in the SHR in
vivo, and either reduced or delayed mortality.

The results suggest

that attendant hypothyroidism may play a more significant role in the
development of impaired cardiac function in diabetic SHR than it does
in normotensive rats.

The possible contribution of left ventricular

hypertrophy to this phenomenon remains to be studied.

These results

may have some clinical applicability.

Whether or not hypertension
occurs more frequently among diabetic patients 47 , it is generally
regarded as an important risk factor for the higher cardiovascular
1 47
morbidity and mortality in this group '

The incidence of impaired

thyroid function among diabetics may be as high as 30\, is most
severe during poor metabolic control, and is most evident in IDDH

23

While diabetic patients with hypothyroidism may be at increased risk
of cardiovascular morbidity and mortality
intensified by hypertension.
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48

, this risk may be further
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Lancet 1:

TABLE 1.

Serum glucose, insulin, triiodothyronine and thyroxine levels of
nondiabetic, diabetic and treated SHR.

Group

n

Glucose

Insulin

T3

(mg/dll

(µU/mll

(ng/dll

94

t

17

6.96

t

1. 53

12

122

t

22

56

Diabetic

9

540

t

61*

14 t

7*

53

t

13*

2.92

t

0.58*

T3-treated diabetic
LI-treated diabetic

9

578

t

87*

18

t

7*

73

t

13

0.28

t

0.09**

7

546

t

116*

229

t

129**

77 t 15

5.46

t

0.94

PZI-treated diabetic 7

370

t

179**

355

t

183**

85

t

22

5.49

t

1. 57

r 3-treated control

7

115

t

12

67

t

15

88

t

26

0.34

t

0.12**

FR control

9

120

t

36

42

t

29

88 t 14

4.36

t

1.31**

OHG control

9

136

t

20

50

t

13

87

5.87

t

1.01

Nondiabetic

t

25

t

23

Values are means i SD, obtained 8 weeks after initiation of diabetes or
treatment.

r 3, triiodothyronine; T4, thyroxine; LI, lente insulin; PZI,

protamine zinc insulin; FR, food restricted nondiabetic group; OHG
3-0-methylglucose pretreated, STZ-injected group.
from the nondiabetic group.

*Significantly different

**Significantly different from the nondiabetic and

diabetic groups.
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TABLE 2.

Body and heart weights of nondiabetic, diabetic and treated SHR.

aw
Group

n

Nondiabetic

12

Diabetic

9

(g)

324:t28
208:t20 *

HW

HW/BW

LV/BW

LV/RV

(mg)

(mg/g)

(mg/g)

(mg/mg)

1370:tl32

4.24:t0.46

3.4l:t0.38

4.38:t0.30

3.48:t0.24

907:t 85 *

9

179:t26 **

7

283:t24

PZI-treated diabetic 7

312:t27

T treated contol
3
FR control

7

300:t20

9

241!11 ** 1064:tll2

OMG control

9

328t24

T -treated diabetic
3
LI-treated diabetic

tt

929:tl46 *

5.56:t0.81
5.25:t0.61
t

5.22:t0.69 *

4.ll:t0.59

4.29t0.25

3.4lt0.21

6.16:t0.56

137l:t 83

4. 4l:t0. 36

3.60t0.32

5.40:t0.56

1406:t 75

4.72t0.55

3.79t0.49

5.44:t0.68

4.4lt0.39

3.62t0.38

6.04:t0.77

4.19:t0.24

3.43:t0.21

6.16t0.56

1213tll2

tt

tt

1370t 94

4. 93t0. 51

Values are means t SD, obtained 8 weeks after initiation of diabetes or
treatment.

BW, body weight; HW, heart weight; LV, left ventricular weight; RV,

right ventricular weight; T , triiodothyronine; LI, lente insulin; PZI,
3
protamine zinc insulin; FR, food restricted nondiabetic group; OMG,
3-0-methylglucose pretreated, STZ-injected group.
from the nondiabetic group.

tt

•Significantly different

Significantly different from the nondiabetic and

diabetic groups.
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TABLE 3.

Hortality of nondiabetic, diabetic and treated SHR .

Hor tali ty
Group

s·

Fraction

\

1/18

5.6

21/33

63.6

T3-treated diabetic
LI-treated diabetic

1/14

7.1

1/10

10.0

PZI-treated diabetic

1/10

10.0

T -treated control
3
FR control

0/12

0

3/13

23 . 1

OHG control

0/10

0

Nondiabetic
Diabetic

SThe values represent the proportion of animals which had died
during the eight week study period.

r 3, triiodothyronine; LI,

lente insulin; PZI, protamine zinc insulin; FR, food restricted
nondiabetic group; OHG, 3-0-methylglucose pretreated, STZ-injected
group.
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TABLE 4.

Systolic arterial pressure and heart rate of nondiabetic, diabetic
and treated SHR.

SAP (kPa)
Group

n

Week 0

HR (beats/min)

Week 8

Week 0

Week 8

12

24.0

t

3.7

26.7

t

2.9

385

t

47

401

t

34

Diabetic

9

23.7

t

2.5

21.1

t

1. 9*

366

t

28

273

t

22*

r 3 -treated diabetic

9

24.8

t

1.9

24.4

t

4.1

407

t

46

413

t

37

I-treated diabetic

14

23.7

t

1. 6

26.5

t

3.3

397

t

35

366

t

42

T -treated control
3
FR control

7

24 .0

t

1.1

30.0

t

3.5

405

t

33

429

t

60

9

25.3

t

1.9

26.3

t

2.0

372

t

18

358

t

40

OHG control

9

23.6

t

2.4

29.7

t

3.5

377

t

19

384

t

27

Nondiabetic

Values are means i SD, obtained before (Week 0) and 8 weeks after initiation of
diabetes or treatment.

SAP, systolic arterial pressure; HR, heart rate; T3 ,

triiodothyronine; I, PZI and Lente insulin; FR, food restricted nondiabetic
group; OHG, 3-0-methylglucose pretreated, STZ-injected group.
different from the nondiabetic group.
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*Significantly

TABLE 5.

Left ventricular pulse pressure (LVPP), stroke work and contractility
(LV+dP/dt) of SHR perfused hearts under various experimental
conditions.

Group

LVPP

n

Stroke Work

(kPa)

Nondiabetic

12

21. 6

t

LV+dP/dt
(kPa/sec)

(mJ/g)

1. 8
t

913 .t 124

2.47

t

0.46

1. 76

t

0.42

2.57

t

0.47

854 t 120

t

572 t 132

9

15.5

t

1.8

T3-treated diabetic 9
I-treated diabetic 14

18.7

t

0.8

21.3 .t 2.5

2.49 .t 0.48

851±177

T -treated control
3
FR control

7

23.3 !. 1. 9

2.76 + 0.31

1101 ±. 147

9

20.0

t

2.3

2 36

t

0.66

802 ±. 162

OHG control

9

23.5

t

2.9

2.48

t

0.56

917 ±. 139

Diabetic

Values are means

t

...

t

SD, obtained 8 weeks after initiation of diabetes or

Left atrial filling pressure was fixed at 20 cm H o and resistance
2
to aortic ejection was fixed at 1.54 kPa/cm 3 •min- 1 . Values for LVPP and stroke
treatment.

work of the first four groups are also depicted in Figure 2.

I-PZI or Lente

insulin; T3 , triiodothyronine; FR, food restricted nondiabetic group; OHG,
3-0-methylglucose pretreated, STZ-injected group.
Significantly different
from the nondiabetic group.

...

•

Significantly different from the nondiabetic and

diabetic groups.

-41-

TABLE 6:

Myocardial oxygen consumption (V0 2 l, cardiac output (CO), power and
efficiency of contraction (El of nondiabetic, diabetic and treated SHR.

co

vo 2
Group

n

Nondiabetic

Po11er

(µL0 /sec•g -1 ) (cm 3/sec•g -1 )
2

(mW/g)

E

(mJ/µL0 l
2

12

4.78

t

0.81

0.49

t

0.08

9.30

t

1. 84

1. 94

t

0.21

9

4.26

t

0.39

0.51

t

0.07

7.53

t

1. 50

1. 76

t

0. 24

T -treated diabetic 9
3
I-treated diabetic 14

6.24

t

1.68

0.64

t

0.12

11. 49

t

2.14

1.92

t

0.40

5.29

t

0.92

0.53

t

0.07

9.93

t

2.07

1. 88

t

0.27

T3-treated control
FR control

7

5.98

t

1.15

0.53

t

0.06

11. 07

t

1.62

1.89

t

0.24

9

6.16

t

2.12

0.52

t

0.13

9.58

t

2.98

1.58

t

0.31

OHG control

9

4.83

t

0.88

0.43

t

0.07

8. 91

t

2.01

1.83

t

0.22

Diabetic

Values are mean

t

t

SD, obtained 8 11eeks after initiation of diabetes or

Left atrial filling pressure 11as fixed at 15 cm H o and resistance
2
3
1
to aortic ejection was fixed at 1.54 kPa/cm •min- • I-PZI and Lente insulin;
treatment.

T , triiodothyronine; FR, food restricted nondiabetic group; OHG,
3
3-0-methylglucose pretreated, STZ-injected group. *Significantly different
from the nondiabetic group.

-42-

TABLE 7.

Coronary flow rate (CFR) and coronary vascular resistance (CVR) of
nondiabetic, diabetic and treated SHR.

CFR
(cm3/sec)

(cm /sec . g

12

0.40

t

0.08

0. 30

t

0.06

50.20

t

3.14

Diabetic

9

0. 23

t

0.04*

0.26

t

o.os

49 . 22

t

3.26

T -treated diabetic
3
I-treated diabetic

9

0.31

t

0.08

0.34

t

0.09

40.64

t

3.88

14

0.41

t

0.07

0.31

:t

0 .OS

45.26

t

3.36

T3-treated control
FR control

7

0.45

:t

0.08

0.32

t

0.06

50.42

:t

4.70

9

0.33

t

0.11

0.31

t

0.10

48.86

t

5. 56

OHG control

9

0.38

:t

0.08

0.29

t

0.06

50.39

t

3.42

Group

Nondiabetic

CFR values are means

n

t

CFR
3

-1

SD and CVR values are means

initiation of diabetes or treatment.

CVR

:t

)

3

(kPa/cm . sec

-1

.g

-1

)

SE, obtained 8 weeks after

CFR was measured when left atrial filling

pressure was fixed at 15 cm H o and resistance to aortic ejection was fixed at
2
3
1
1 . 54 kPa/cm •min- • CVR is determined by plotting mean aortic pressure against
coronary flow at the four resistances to aortic ejection, and obtaining the
slope of the regression (see Methods).

I-PZI and Lente insulin; T3 ,
triiodothyronine; FR, food restricted nondiabetic group; OHG, 3-0-methylglucose

pretreated, STZ-injected group.

*Significantly different from the nondiabetic

group.
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Figure 1.

(A) Systolic arterial pressure (SAP) and (B) heart rate

(HR) in vivo, of nondiabetic (0), diabetic (e), insulin-treated
diabetic (•) and triiodothyronine (T )-treated diabetic (•) SHR. The
3
number of animals in each group is shown in parentheses. Values are
means ±SD, obtained 8 weeks after initiation of diabetes or
treatment.

*Significantly different from the nondiabetic group.
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Figure 2.

Cardiac performance ex vivo, as measured by (A) left

ventricular pulse pressure (LVPP) or (Bl stroke work, of nondiabetic
(0), diabetic (el, insulin-treated diabetic

(~,

and triiodothyronine

(T J-treated diabetic ~) SHR. The hearts were volume loaded by
3
varying left atrial filling pressure (LAFP) between 5 and 20 cm H o.
2
Resistance to left ventricular ejection was fixed at 1.54
3
-1
kPa/cm .min .

Values are means t SD, obtained 8 weeks after

initiation of diabetes or treatment (n=7-12 per group).
*Significantly different from the nondiabetic group.
different from the nondiabetic and diabetic groups.
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**Significantly
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Figure 3.

Cardiac performance ex vivo, as measured by (A) left

ventricular pulse pressure (LVPP) or (B) stroke work, of nondiabetic
(()), diabetic (el, insulin-treated diabetic (II), and triiodothyronine
(T J-treated diabetic (•l SHR.
3

The hearts were pressure loaded by

varying resistance to aortic ejection between 0.19 and 3.13

3
-1
kPa/cm .min .

Left atrial filling pressure was fixed at 15 cm H o.
2

Values are means i SD, obtained 8 weeks after initiation of diabetes
or treatment (n=7-12 per group).
nondiabetic group.
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*Significantly different from the
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Figure 4.

Left ventricular pressure (LVP) waves from perfused

working hearts of nondiabetic, diabetic, insulin-treated diabetic and
triiodothyronine (T )-treated diabetic SHR, under increasing
3
pressure-loading conditions.

Each of the four superimposed LVP waves

was obtained at one of four resistances to aortic ejection:

3
-1
0.41, 1.54 and 3.13 kPa/cm .min .
fixed at 15 cm H o.
2

0.19,

Left atrial filling pressure was

LVP waves were recorded from a single heart in

each group and were obtained eight weeks after initiation of
untreated or treated diabetes.

Analog signals were digitized and

stored on a diskette and regenerated using an IBM PC II with ASYST(R)
software and an HP7470 plotter.

Individual records were selected

with the aim of approximating, as closely as possible, the mean
maximum LVP values for each group as shown in Figure 3A.
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Ventricular Relaxation of Diabetic Spontaneously
Hypertensive Rat

-52-

SUMMARY
Diabetes - and possibly the hypothyroidism which attends
diabetes - impairs mechanical relaxation of ventricular muscle, in
part by depressing the rate of Ca 2+ uptake by sarcoplasmic reticulum.
Left ventricular hypertrophy exacerbates the adverse effects of
diabetes on cardiac performance but its effects on relaxation
variables have not been well characterized.

We examined the impact

of streptozotocin-induced diabetes (8 weeks) on ventricular pressure
load-dependent relaxation and sarcoplasmic reticular calcium uptake
of hearts from spontaneously hypertensive rats and Wistar Kyoto rats.
Subsets of diabetic hypertensive rats were treated with either
insulin (10 U/kg/day) or triiodothyronine (8-10 µg/kg/day).

Diabetes

impaired load-dependent relaxation and depressed sarcoplasmic
reticular calcium uptake only in spontaneously hypertensive rat
hearts.

Either insulin or triiodothyronine treatment prevented the

diabetes-induced depressions of both mechanical and biochemical
indices of relaxation.

The results suggest that: 1) Hypertrophic

ventricles of spontaneously hypertensive rats are more susceptible to
the detrimental effects of diabetes on relaxation indices than are
the nonhypertrophic Wistar Kyoto rat ventricles; and 2) The
hypothyroidism which attends diabetes may contribute to the impaired
relaxation of diabetic spontaneously hypertensive rat left ventricle.
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INTRODUCTION
Impaired mechanical relaxation is an important component of the
adverse effects of diabetes on cardiac performance

1-3

Diastolic

dysfunction involving prolonged relaxation is an early indication of
clinical diabetic cardiomyopathy 415

Characteristics of abnormal

ventricular relaxation in diabetes include increased durations and
reduced rates of decline in either the tension of isolated muscle

1

or

the pressure of the intact ventricle 213
One mechanism by which diabetes produces an impairment of
ventricular muscle relaxation may involve the rate of calcium
sequestration by the sarcoplasmic reticulum (SR).

This biochemical

6
measurement is assumed to be a determinant of mechanical relaxation .
Diabetes often depresses SR calcium uptake, and the activity of the
SR ca 2+ -Mg 2+ -ATPase, in rat ventricle 7- 10 .
Recent evidence suggests that left ventricular hypertrophy (LVH)
.

1 11-13

exacerbates functional defects of diabetic myocardium '

,

including those which may have an impact on ventricular relaxation.
The presence of LVH alone may or may not be associated with impaired
relaxation 14 - 17 .

However, when diabetes coexists with LVH in the

spontaneously hypertensive rat (SHR), the rate of left ventricular
pressure decline of perfused hearts is more profoundly depressed when
. be t es in
. normo t ens1ve
.
. ll, 13 .
compare d t o th e e ff ec t s o f d ia
ra t s t rains
Isometric relaxation is also prolonged in hypertrophic papillary
muscles from the diabetic renovascular hypertensive rat

12

These

results would suggest that combined effects of diabetes and LVH on SR
Ca

2+ uptake might be more pronounced than the influence of either

condition individually.

However, the interaction between diabetes

-54-

and LVH on the relationship between myocardial relaxation and SR
calcium uptake has not been characterized.
Reduced serum levels of thyroid hormones are often associated
with diabetes

112112

, and this hypothyroidism (or "low thyroid state")

may contribute to diabetic cardiomyopathy.

Thyroid hormone

deficiencies, like diabetes, can lead to prolonged relaxation and
. 18 19
depressed rates of SR calcium uptake in the myocardium ' .

The

effects of hypothyroidism on these measurements are well correlated,
both in nonhypertrophic and hypertrophic ventricles

20

.

Treatment of

the diabetic SHR with triiodothyronine (T ) effectively prevents the
3
21
resultant cardiac dysfunction , but the influence of r treatment in
3
22
24
.
d.ia be t ic
. ra t mo d e 1s is
. incons1s
.
. t en t - .
non hyper t ens1ve
Circumstantial evidence therefore provides a rationale for the
following hypotheses:

1) The impairment in mechanical relaxation

caused by diabetes can be correlated with the depression of SR ca 2+
uptake activity; 2) Both of these effects of diabetes are more
pronounced on hypertrophic ventricles than they are on
nonhypertrophic ventricles; and 3) Attendant hypothyroidism
contributes to the effects of diabetes on mechanical and biochemical
indices of ventricular relaxation in the SHR.

The results of the

study provide evidence in support of each hypothesis, demonstrating
that T treatment can prevent both mechanical and biochemical defects
3
in relaxation of the diabetic hypertrophic ventricle in the SHR
model.
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METHODS
Animal Groups.

Male SHR and Wistar Kyoto (WKY) rats were purchased

from Charles River Breeding Labs (Wilmington, MA), then housed
communally by strain and fed ad libitum.

At 15 weeks of age, animals

were weight matched and divided into either diabetic or nondiabetic
groups.

Diabetes was induced in lightly etherized animals by a

single tail vein injection of streptozotocin (STZ; Sigma Chemical
Co., St. Louis, MO).

The dose of STZ for each strain was adjusted in

order to induce similar degrees of diabetes as assessed by serum
glucose concentrations.

Based on preliminary results, equieffective

doses of STZ in the WKY and SHR strains, as indexed by serum glucose
elevations, were determined to be 50 mg STZ/kg BW and 45 mg STZ/kg BW
respectively.

The STZ was dissolved in citrate buffer (0.1 Hat pH

4.5) just prior to use.

The nondiabetic animals were also etherized

and were injected with comparable volumes of the citrate buffer
alone.

Urinary glucose was detected in all animals of the diabetic

groups (DIASTIX(R)).

All animals were sacrificed eight weeks later.

The diabetic SHR were divided into three subgroups corresponding
to the treatment regimes initiated three days after STZ injection:
1) protamine zinc insulin (I; Eli Lilly Co., Indianapolis, IN, 10
U/kg/day sc); 2) T (Sigma, 8-10 µg/kg/day sc); and 3) untreated.
3

We

observed initially that treatment of diabetic SHR with 10 µg/kg/day
of T was sufficient to just reverse the bradycardia in vivo. After
3
6 weeks of T treatment, the dose was reduced to 8 µg/kg/day in order
3
to avoid a progressive T -induced tachycardia (see accompanying
3
manuscript). The nondiabetic SHR were subdivided into two groups of
untreated and T -treated (8-10 µg/kg/day sc) animals.
3
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Treatment of

diabetic WKY with either insulin or T was unnecessary, because
3
initial studies had shown that diabetes had little or no effect on
mechanical indices of ventricular relaxation in this strain (see
Results).
In Vivo Measurements.

Systolic arterial pressure (SAP), heart rate

(HR) and body weight (BW) were taken just prior to the tail vein
injections, and then four and eights weeks later.

A standard

tail-cuff sphygmomanometer within a temperature controlled chamber
(34°C) was used to measure SAP and HR, after the animals were
prewarmed for 10-15 minutes.

All measurements were recorded prior to

the daily injections of T or insulin.
3
Serum Assays. Eight weeks after they were injected with STZ or
citrate buffer, the animals were rapidly decapitated, and their serum
was collected and stored at -20°c.

The rats received the final

injection on the day prior to sacrifice.

The degree of diabetes was

evaluated by serum glucose concentration using a glucose oxidase
assay (Sigma).

Animals were classified as diabetic if serum glucose

values exceeded 300 mg/dL.

Radioimmunoassays were used to determine

serum insulin (Micromedic Systems Inc., Horsham, PA) and total T and
3
thyroxine (T l concentrations (Cambridge Medical Diagnostics,
4
Billerica, MA).

Rat insulin was generously supplied by Dr. R. Chance

(Eli Lilly) and was used as the standard for the insulin assays.
Heart Perfusion.

A subset of each animal group was used to assay

left ventricular (LV) relaxation of isolated perfused working hearts.
The hearts were quickly excised and perfused as described
previously11

In brief, the perfusion apparatus was designed to

manipulate LV pressure loads by altering resistance to aortic

-57-

ejection (see below).

Left ventricular pressure (LVP) was

continually monitored through an intraventricular cannula coupled to
a pulse transducer (Statham, Hato Rey, PR).

The aorta was tied to a

14 gauge cannula and the heart was first perfused in a retrograde
fashion for 3-5 min, then in the working mode for the remainder of
the experiment.
The hearts were perfused (nonrecirculating) with Krebs-Henseleit
buffer maintained at 37°c.

The buffer composition was 120 mH NaCl,

5.6 mH KCl, 0.65 mH HgS0 , 1.21 mH NaH Po , 25 mH NaHC0 , 2.4 mH
4
2 4
3
cac1 , 0.2 mH EDTA and 10 mH glucose (pH 7.4 when warmed and gassed
2
with 95\ o and 5\ co J. Hearts were paced at 300 beats per minute
2
2
with a bipolar stimulating electrode placed on the right atrium.
Prior to data collection, LVP was monitored in the working heart
continually for 10-15 minutes on a Narcotrace Model 80 chart recorder
(Narco Biosystems, Houston, TX) interfaced with a dedicated digital
computer (Buxco Corp., Sharon, CT) to ensure stability to each
preparation.

During this time, left atrial filling pressure (LAFP)

was fixed at 15 cm H o and resistance to aortic ejection was set at
2
3
-1
1.54 kPa/cm •min . Aortic flow could be directed through one of
four segments of PE tubing, the length and diameter of which was
varied in order to impose a final resistance of either 0.19, 0.41,
1.54 or 3.13 kPa/cm3 •min-l (calibrated at constant flow).
Quantification of Left Ventricular Relaxation.

Samples of the LVP

waves were taken during pressure loading at the four aortic
resistances and at constant LAFP (15 cm H 0J.
2
recorded and stored in an IBM PC II.

LVP waves were

Data acquisition was

accomplished, in part, with the aid of A/D conversion hardware (Data
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Translation, Marlborough, MA) and ASYST(R) software (Macmillan
Software Co., New York, NY).

At each pressure load, a series of five

sequential LVP waves was recorded using an external trigger signal to
initiate the data acquisition.

Measurements obtiined from the

digitized left ventricular waveforms (see Figure 1) included maximum
left ventricular pulse pressure (P

max

), the time from the onset of

LVP rise at end-diastole to Pmax (Tp)' the time from Pmax to minimum
diastolic LVP (T ), and the maximum rate of LVP decline (LV-dP/dt).
r

Maxima and minima of the LVP wave were obtained at the time points
corresponding to zero value of the first derivative.
the LVP wave over T

r

The area under

(A ) was used to quantify pressure
r

load-dependent relaxation

16

.

For each heart and at each pressure

load, P
was plotted against Ar; the slope of the regression line
max
through the four points was used as the relaxation index (P
/A).
max r
Preliminary studies showed that sampling and averaging of successive
pressure waves was unnecessary because the variability between waves
never exceeded 0.1\.

The resolution of the digitized and stored

waveform was 1 msec, each point representing the average of 400 2.5
µsec samples.
The hearts were removed from the perfusion apparatus and blotted
dry after the data collection.

The aorta and excess connective

tissue were trimmed away and the following wet weights were obtained:
whole heart (HW): left ventricular (LV) including the septum, and
right ventricular (RV).

These heart weights were used to assess the

degree of ventricular hypertrophy.
SR Calcium Uptake.

Microsomes were prepared from left ventricular

tissue of subgroups within each experimental group.
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Membrane

fractions enriched with SR were isolated either from single left
ventricles or from pools of two left ventricles, as determined by
preliminary studies of SR protein yield, by the method of Penpargkul
et al.

9

with minor modifications.

The need for pooling explains the

differences in total sample size between groups in, for example,
Tables 1 and 5.

The hearts were removed, quickly trimmed, weighed

and homogenized in 12 mL of a medium containing 0.3 M sucrose and 10
mM imidazole (pH 7.4).
at 2,000 x g.

The homogenate was centrifuged for 15 minutes

The supernatant was then centrifuged at 8,700 x g for

another 15 minutes.

The second supernatant was centrifuged a third

time at 50,000 x g for 30 min.

The pellet was resuspended in 10 rnL

of 0.6 M KCl and 10 mM imidazole (pH 6.8), and centrifuged at 50,000
x g for 30 minutes.

The final pellet was resuspended in 2-3 rnL of 50

mM KCl and 10 mM imidazole to yield a final concentration of

approximately 100 µg/100 µL 9 .
Calcium uptake was determined by using the Millipore filtration
technique. Cardiac microsomes were characterized in the presence and
absence of sodium azide, KCl, ATP and oxalate.

Microsomes were

pre-incubated for 3 min in 1 mL final volume, containing 5 mM ATP,
120 mM KCl, 40 mM histidine HCl, 5 mM oxalate, 5 mM sodium azide, and
5 mM HgC1

2

(pH 6.8 at 37°CJ.

The reaction was initiated by adding a

solution containing EGTA, 45 Ca and nonradioactive Cac1 . The final
2
concentration of EGTA was constant at 100 µH. Free calcium
concentrations were calculated to range between 0.18 and 5.62 µH 25 .
The reaction was terminated by filtering over 0.45 micron Millipore
filters and washed with 2 mL Tris-HCl (20 mM).

Filters were dried,

counted in a liquid scintillation counter in 5 mL scintillation fluid
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(BetaBlend(R), ICN Radiochemicals, Irvine, CA).

Protein

concentrations were determined by the method of Lowry et al.

26

.

Rates of SR calcium uptake were expressed as µmoles/mg protein •
min- 1 . Blanks consisted of microsomal preparations in the absence of
added ATP.
Statistical Analyses.

The effects of diabetes and the hormone

treatments of SHR were evaluated by one- or two-factor analysis of
variance (ANOVA) with repeated measures when appropriate (Statistical
Analysis Systems, Cary, NC).

Comparisons between rat strains were

made using two- or three-factor designs, with repeated measures when
appropriate.

Significance was set at the 0.05 level.

Simple effects

and Student Newman-Keuls multiple comparisons tests were used to
evaluate significance.

The mean square error term(s) from the parent

ANOVA were used to calculate all follow-up statistics.
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RESULTS
Serum Assays.

The injections of STZ induced a degree of diabetes, as

quantified by serum glucose and insulin levels, which was equivalent
in the SHR and WKY rat strains (Table 1).

The diabetic animals were

characterized by depressed serum T and T levels.
3
4

The magnitudes of

the depressions in thyroid hormone concentrations were about the same
in the two strains, although both T and T levels of nondiabetic SHR
3
4
were slightly higher than those of the nondiabetic WKY.
Treatment of diabetic SHR with T prevented the decline in serum
3
T levels, but had no effect on the elevated serum glucose or
3
depressed insulin values (Table 1).

It also exacerbated the decline

in serum T , probably by inhibiting TSH production and glandular T
4
4
secretion.

T treatment of nondiabetic SHR had the same effect on T
3
4

levels, but otherwise did not alter glucose, insulin or T values.
3
Treatment of diabetic SHR with insulin did not correct the
hyperglycemia, at least at the 15-20 hour time point, even though it
caused a pronounced increase in immunoreactive insulin activity
(Table 1).

This pattern may be evidence for subsensitivity to

exogenous insulin in diabetic SHR.

Insulin treatment was only

partially effective in restoring serum T and T to normal.
3
4
Body and Heart Weights.

As

expected, nondiabetic SHR had lower BW,

but higher ratios of LV weight to either BW or (RV weight), than did
nondiabetic WKY (Table 2).

Thus, the left ventricles of SHR were

both relatively (LV/BW) and absolutely (LV/RV) hypertrophic

11

Diabetes reduced BW and HW of SHR and WKY rats, and reduced LV/RV of
SHR without affecting LV/BW.

This indicates that diabetes had no

-62-

effect on relative hypertrophy, but reversed absolute hypertrophy of
SHR left ventricles

11

.

Treatment of diabetic SHR with T caused a further decline in
3
BW, but had no effect on HW, thus it increased LV/BW (Table 2).
However, T3 had no effect on LV/RV, and therefore did not affect the
reversal of hypertrophy induced by diabetes.

Treatment of

nondiabetic SHR with T had no effect on any of the body or heart
3
weight measurements.
Insulin treatment (Table 2) nearly restored BW to normal, and
prevented the declines in HW and LV/BW in diabetic SHR, in spite of
its failure to correct the hyperglycemia 1
Arterial Pressure and Heart Rate In Vivo.

As

expected, nondiabetic

SHR were hypertensive and tachycardic compared to the WKY animals
(Table 3).

The diabetic SHR were characterized by depressed SAP and

11
. .
.
.
HR a ft er 8 wee ks, con f irming
previous
observa t ions

However,

diabetes had no effect on these measurements in the WKY strain.
Treatment of diabetic SHR with T , at a dose which was adjusted
3
to prevent the bradycardia, only partially reversed the depressor
effect of diabetes (Table 3).

In contrast, insulin treatment

prevented the decline in SAP but did not fully restore HR to normal.
Treatment of nondiabetic SHR with T had no significant effect on
3
either SAP or HR.
Left Ventricular Pressure Wave Characteristics.

Perfused hearts from

nondiabetic SHR had a shorter Tr but otherwise did not differ from
those of the WKY strain with regard to Pmax , Tp, and LV -dP/dt (Table
4).

Diabetes increased Tp of both SHR and WKY hearts, but increased

Tr and reduced Pmax and LV-dP/dt only in the SHR.
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None of these

changes was associated with differences in coronary flow or
resistance, either within or between strains, confirming previous
observations 11120 (data not shown).
All of the effects of diabetes on left ventr'icular pressure wave
characteristics in the SHR strain were prevented by either T or
3
insulin treatment (Table 4).

However, none of these measurements was

altered by T treatment of nondiabetic SHR. The effects of diabetes
3
and treatment with either insulin or T on LVP waveforms are
3
illustrated in Figure 1.
Pressure Load-Dependent Relaxation and SR Ca

2+

Uptake.

Pressure

load-dependent relaxation of SHR ventricles was impaired by diabetes,
but that of the WKY hearts was not affected (Table 5, Figure 2).

The

rate of left ventricular SR calcium uptake was also depressed by
diabetes only in the SHR (Table 5, Figure 3), so that the effects of
diabetes on the two variables were well correlated between
experimental groups.

Both the mechanical and biochemical defects of

diabetic SHR ventricle were reversed by either insulin or T3
treatment (Table 5, Figures 1-3).

Therefore, T3 treatment was as

effective as insulin therapy in preventing the impairment in
mechanical relaxation, and the depressed SR calcium uptake activity,
of diabetic SHR ventricle.

Treatment of nondiabetic SHR with T3 had

no significant effect on either the relaxation index (Table 5, Figure
2) or the rate of SR calcium uptake (Figure 3).
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DISCUSSION
A common biochemical defect of diabetic myocardium is a
depressed rate of calcium sequestration by SR microsomes 7 .

Proposed

mechanisms include reductions in either the density or the activity
2
2
of ca +-Hg + ATPase 819118 , alterations in membrane lipid

profiles 8127128 , and changes in the degree of membrane
phosphorylation

29

Until now, studies of this kind have been

restricted to nonhypertensive, nonhypertrophic models.

Our data

suggest, however, that the adverse effect of diabetes on left
ventricular SR calcium uptake activity is exacerbated by preexisting
LVH (Figure 3, Table 5).

Thus, diabetes of equal duration and

severity - as measured by serum glucose and insulin levels depressed SR Ca

2+

uptake of SHR left ventricles, but had no effect in

the nonhypertensive, nonhypertrophic WKY strain.

These results

extend those of earlier studies which had demonstrated that the
detrimental effects of chronic diabetes on various indices of cardiac
mechanical activity are more pronounced on hypertrophic than on
nonhypertrophic ventricles of both SHR and renovascular hypertensive
ra t s

11-13

.

(See accompanying manuscript.)

The mechanism for the apparent interaction between diabetes and
LVH on SR Ca

2+

uptake is a matter of speculation.

In nondiabetic

. ven t r1c
. 1 e, SR Ca 2+ up t a ke m1g
. ht be impa1re
.
. d 2o, 3o or
hyper t rop h ic
normal

31

, depending perhaps on either the experimental model or the

duration of hypertension

32

Like diabetes, LVH is associated with

alterations in lipid metabolism33134 and restricted fuel source
ava1·1 a b"l"t
i i y 35,36

Elevated workloads, reduced coronary reserve

and possibly increased metabolic demand for carnitine
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33

37

(see below)

may combine to predispose the hypertrophic ventricle to
membrane-disrupting effects of diabetes which might otherwise be less
apparent in the absence of preexisting LVH.
Our results also show that the activity of SR ca 2+ uptake was
well correlated with indices of mechanical relaxation.

Both

measurements were depressed in the diabetic SHR, but neither one was
significantly affected in any other experimental group (Table 5,
Figure 3).

Cardiac muscle relaxation can be categorized as

consisting of inactivation-dependent and afterload-dependent
mechanisms; the latter is considered to be more closely linked to
38
intracellular calcium sequestering mechanisms
Load-dependent
relaxation is most often demonstrated in isolated ventricular muscle
preparations.

A recent report from this laboratory suggested that

the ratio Pmax/Ar can serve as an index of load-dependent relaxation
in the ejecting ventricle 16 . As expected, the value of P
/A in
max r
2+
the present study correlated with the rate of SR Ca
uptake between
experimental groups (Table 5, Figures 2 and 3).

The T variable did
r

not correlate as well, because it differed between nondiabetic SHR
and WKY groups, whereas the SR ca 2+ uptake activity did not (Tables 4
an d 5) .

.
repor t
I n con t ras t t o th e resu lt s o f th e previous

study LV -dP/dt varied with P
/A .
max r

16

. th"is
, in

However, the former variable is

inconsistent and difficult to interpret, largely because of its
dependence on the configuration of the pressure wave.

Overall, our

results strongly suggest that diabetes impairs load-dependent
relaxation of hypertrophic ventricle, although diabetes likely
compromises inactivation-dependent relaxation mechanisms as
we 11 1,12,38 .

Whether or not diabetes can specifically depress
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load-dependent relaxation of nonhypertrophic myocardium remains to be
determined.
The effectiveness of T treatment to completely prevent the
3
diabetesinduced impairments in relaxation and SR

ca 2+

uptake of SAR ventricle

(Tables 4 and 5, Figures 2 and 3) was somewhat surprising.

In two

previous reports, hypothyroidism induced in SHR by either
methimazole 11 or thyroidectomy

20

only partially duplicated the

effects of diabetes on mechanical function.

In normotensive diabetic

rats, insulin therapy can ameliorate impaired mechanical function
without completely correcting the depressed serum thyroid hormone
levels 1 .

The dose of T used in the current study, 8-10 µg/kg/day,
3

was selected on the basis of its ability to restore the depressed HR
in vivo of diabetic SHR to normal (see Table 3).

This dose probably

did not impose a hyperthyroid state in the diabetic SHR for several
reasons: 1) It did not significantly increase serum T levels above
3
those of the nondiabetic controls, although it apparently did inhibit
T production by the thyroid gland (Table l); 2) The same dose given
4
to the nondiabetic SHR had no effect on heart or body weights, or on
SAP or HR in vivo (Tables 2 and 3); 3) T3 treatment of nondiabetic
SHR also had no significant effect on either serum T levels (Table
3
2
1), indices of mechanical relaxation, or the rate of SR ca + uptake
in vitro (Tables 4 and 5).

Earlier studies had indicated that

"physiological doses" of thyroid hormone - i.e., those which had been
shown to be sufficient for replacement therapy of simple
hypothyroidism - were only partially effective in restoring cardiac
function of diabetic normotensive rats 8122123124 .
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Interestingly,

however, T (10 µg/kg, twice/day) given for only the final 5 days of
3
a 2-week period of diabetes, almost completely reversed the prolonged
action potential duration in diabetic Wistar rat atria

39

.

Our results suggest that hypertension, and probably left
ventricular hypertrophy, increase the responsiveness of diabetic
myocardium to the ameliorative effects of T therapy, at least with
3
regard to mechanical and biochemical indices of relaxation.

The

mechanism may involve, in part, differential effects of diabetes on
membrane lipid profiles, and other aspects of lipid metabolism, of
hypertrophic vs. nonhypertrophic ventricle.

The acute effects of T
3
2
2
on ca +-Hg +-ATPases are profoundly influenced by the lipid
environment 40 .

Because hypertrophy 41 , hypothyroidism 40 and

diabetes 42 all affect membrane lipid composition, it seems reasonable
to hypothesize that different combinations of these pathophysiologic
conditions would have variable influences on the subsequent effects
of T administration.
3

In normotensive rats, myoinositol

coadministration increases the therapeutic efficacy of T in diabetic
3
43
cardiomyopathy
Fatty acyl esters of carnitine may be especially
important.

Enhanced incorporation of long chain acyl carnitines

(LCAC) into the SR membrane is correlated with depressed rates of
calcium uptake in diabetes
in SR membranes 44 .

27

and T treatment decreases LCAC levels
3

Another potential mechanism undoubtedly involves

the regulation of SR calcium pump activity by thyroid hormone.
Chronically, T probably increases the rate of SR ca 2+ uptake by
3
accelerating the synthesis of ca 2+-Hg 2+-ATPase enzyme molecules, and
hypothyroidism has opposite effects on these rneasurements
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45

.

The

data from our study (Figure 3) and those of a previous report 16 are
consistent with such an effect of thyroid state in diabetic SHR.
In summary, the results of this study show that the interaction
between diabetes and LV hypertrophy is manifested· by defects in
biochemical and mechanical measurements of ventricular muscle
relaxation.

They also demonstrate that this condition is completely

preventable by treatment of diabetic SHR with T .
3

The possibility

that these two consequences of hypertensive hypertrophy in the SHR
model - exacerbation of diabetic cardiomyopathy and predisposition to
the ameliorative effects of T3 treatment - might be mechanistically
interrelated remains to be investigated.
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TABLE 1.

Serum glucose, insulin, T3 and T4 values of nondiabetic and diabetic
SHR and WKY rats.

Group

n

Glucose

Insulin

T3

(mq/dLl

(µU/mLl

(ng/dLl

~

Nondiabetic

20

124 + 20

68 .i

Diabetic

18

580 + 65 *

16 ±.

Diabetic + T3

18

615 ± 77

Diabetic + I

16

542 + 196

Nondiabetic + T3

15

132 ± 27

69 + 15

Nondiabetic

21

149 ±. 34

77 ±.

Diabetic

16

567 ±. 118 *

22 +

t
t

26
6*

25 + 14

t

287 ± 165 **

y

99 ±. 19y

5.52 ±. 1.93

47 ±. 13 *

2.12 ±. 0.76 *

118 .i 64
71 .i 23 **
109 ±. 50

0.21 + 0.12
4.12 + 1. 60

tt

••

0.27 ±. 0.15 **

m
21

9*

86 ±. 13
41

±. 11 *

4. 62

±. 1.12

2.60 ±. 0.68 *

Values represent means ±. SD, obtained 8 weeks after initiation of diabetes or
treatment.

T , triiodothyronine; I, protamine zinc insulin.
3
Significantly different from the nondiabetic group (within strain).

*
** Significantly

different from the nondiabetic and diabetic groups (within

strain).
Y Significantly different from the nondiabetic WKY.
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TABLE 2.

Body and heart weights of nondiabetic and diabetic SHR and WKY rats.

Group

n

BW

HW

LV/BW

LV/RV

(g)

(mg)

(mg/g)

(mg/mg)

m
.t 25y

Nondiabetic

20

328

Diabetic

18

196 ±. 21

Diabetic + T3

18

174

Diabetic + I

16

305 ±. 25

Nond iabe tic + T3

15

322 ±. 35

21

386 ±. 31

.t

1370

t

.t 132

3.20

y
.t 0. 40 5.37 i0.72y

907 + 85 * 3.04 ±. 0.51

tt

t

.t 0.73

929

.t 146

1371

±. 83

3.00 ±. 0. 59

4.84 ±. 1.11

1406 ±. 75

3.36 ±. 0.58

4.86 ±.0.90

1428 ±. 182

2.66 ±. 0.37

4.31 ±. 0.80

1070 + 75 *

2.75 ±. 0.50

4.13 ±. 0.66

21
tt

t

4.42 ±. 1.04

3.68 i 0.63

4.41

t
t

m
Nondiabetic
Diabetic

16

306 ±. 37

t

Values represent means ±. SD, obtained 8 weeks after initiation of diabetes or
treatment. BW, body weight; HW, heart weight; LV, left ventricular weight; RV,
right ventricular weight; T , triiodothyronine; I, protaaine zinc insulin.
3
* Significantly different from the nondiabetic group (within strain}.
tt

Significantly different from the nondiabetic and diabetic groups (within
strain}.

Y Significantly different from the nondiabetic WKY.
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TABLE 3.

Systolic arterial pressure and heart rates of nondiabetic and
diabetic SHR and WKY rats.

Group

n

SAP (kPal
Week 0

Week 8

HR (beats/min)
Week 0

Week 8

~

Nondiabetic

20

23.6 ± 3.2 1

26.4 .! 24 l

386 .! 40

1

Diabetic

18

23.7 ±. 2. 8

20.0 ±. l. 9*

377 ±. 33

287 t 29 *

Diabetic + T3

18

24.4 ± 2.0

23.6 .±. 3.2 **

390 .±. 40

439 .±. 50

Diabetic + I

16

23.5 ± 2.0

26.9 .±. 2.7

384 .±. 28

389 .! 36 **

Nondiabetic + T3

15

23.7 .±. 1.6

28.2 .±. 3.1

400 .±. 29

456 .±. 57

Nondiabetic

21

17.1±.1.7

18.8 ±. 1. 5

315 ±. 49

302 ±. 29

Diabetic

16

17.3 ±. 1. 7

17.9 ±. 2.3

311 !. 19

275 !. 22

422 .! 46

1

m

Values represent means ±. SD, obtained 8 veeks after initiation of diabetes or
SAP, systolic arterial pressure; HR, heart rate; r ,
3
triiodothyronine; I, protamine zinc insulin.
treatment.

* Significantly different
** Significantly different

from the nondiabetic group (within strain).
from the nondiabetic and diabetic groups (within

strain).
1 Significantly different from the nondiabetic WKY.
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TABLE 4.

Left ventricular pressure wave characteristics of nondiabetic and
diabetic SHR and WKY rat hearts

Group

n

~

Y1:l2_.

Pmax

Tr

LV-dP/dt

(kPa)

(msec)

(kPa/sec)

38 ± 3

83 ± 51'

600 + 92

t

104 + 8*

416 ±. 113

~

Nondiabetic

12

19.1 ± 0.9

Diabetic

9

14.7 ±. 1. 9*

42 ±. 6

Diabetic + T3

9

17.9 ±. 0. 7

34 ±. 5

82 ±. 8

549 + 76

Diabetic + I

7

20.0 ±. 1.5

41 ±. 3

80 ±. 6

601 ±. 70

Nondiabetic + T3

7

20.9 + 1.6

34 + 6

78 + 5

645 ± 105

13

18.9 ±. 2.7

36 ±. 4

99 ±. 9

541 ±. 134

9

17.l ±. 2. 0

45 ±. 5

98 ±. 12

517 ±. 108

t

m
Nondiabetic
Diabetic

t

Values represent means ±. SD, obtained 8 weeks after initiation of diabetes or
treatment.

Pmax' maximum left ventricular developed pressure (LVDPl; Tp' time

to Pmax; Tr' time from Paax to minimum LVDP; LV-dP/dt, maximum rate of left
ventricular pressure decline; T , triiodothyronine; I, protamine zinc insulin.
3
Left ventricular filling pressure was fixed at 15 cm H o and resistance to
2
3
aortic ejection was fixed at 1.54 kPa/cm .min-l.
t

Significantly different from the nondiabetic group (within strain).

1 significantly different from the nondiabetic WKY.
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TABLE 5.

Ventricular relaxation index and SR

ca 2+

uptake of nondiabetic and

diabetic SHR and WKY rats.

Group

n

s

Relaxation Index

SR

(sec -1 )

ca ++

Uptake

(nmoles/mq.min-l)

m
Nondiabetic

12

16.7 ±. 0.6

6

42.3 ±. 7.4

Diabetic

9

12.6 i 1.1 *

4

14.2 i 1.4 *

Diabetic + T3

9

18.8 i 0.7

4

45.7 i 6.0

Diabetic + Insulin

7

18.1 ±. 0.8

4

49.0 ±. 3.8

Nondiabetic + T3

7

17.2 .±. 0.6

4

59.6 + 4.5

13

15.4 ±. 0.9

6

53.4 ±. 3.0

9

13.3 ±. 1.0

4

47.4 ±. 8.3

m
Nondiabetic
Diabetic

Values represent means ±. SE, obtained 8 weeks after initiation of diabetes or
treatment. Microsomal ca 2+ uptake was stimulated by io- 5 · 5 H free calcium (see
· Figure 2). T , triiodothyronine; I, protamine zinc insulin.
3
1 Number of individual perfused hearts .
+Number of groups of pooled left ventricles .

•Significantly different

from the nondiabetic SHR group.

-81-

Figure 1.

Computer print-out of left ventricular pressure (LVP)

waves from nondiabetic (nd), diabetic (d), insulin-treated diabetic
(d+i) and T treated diabetic (d+t ) SHR hearts ex vivo. Each LVP
3
3
wave was recorded from a single heart at a fixed pressure load
3
-1
(resistance to aortic ejection) of 3. 13 kPa/cm .min , and volume
load of 15 cm H o. The LVP waves were chosen in order to closely
2
represent the mean values of contraction and relaxation indices for
each experimental group.

The indices used to assess mechanical

function are depicted on the nondiabetic SHR LVP wave (left) and
include: maximum LVP (Pmax); time to Pmax (T ); total time of
p

pressure decline (Tr); and area under the LVP wave during Tr (Ar).
For further details, see Methods.
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Figure 2.

Pressure load-dependent relaxation of nondiabetic (O),

diabetic (el, insulin-treated diabetic (•), T3-treated diabetic

(~),

and T -treated nondiabetic (~) SHR hearts ex vivo. The four points
3
within each group represent maximum left ventricular pulse pressure
(Pmax) vs. the area under the falling phase of the pressure wave (Ar)
at each of four pressure loads (see Figure 1).

Loading was altered

stepwise by fixing the resistance to aortic ejection at 0.19, 0.41,
3
-1
1.54, or 3.13 kPa/cm .min
(see Methods).

The slope of the

regression line through the four points within each group is the
value of the relaxation index (see Table 5).

Only the untreated

diabetic group was characterized by a significantly depressed
relaxation index.

Therefore, for simplicity, a single line

representing the collective mean slope is depicted for the remaining
experimental groups.

Values represent means (n

= 7-12),

weeks after initiation of untreated and treated diabetes.
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1.0

1.2

Figure 3.

Rate of sarcoplasmic reticular (SR) calcium uptake of left

ventricular microsomes from nondiabetic (0), diabetic (el,
insulin-treated diabetic (Im), T -treated diabetic (•l and T -treated
3
3
nondiabetic
(right).

~)

SHR (left), and nondiabetic (0) and diabetic (I) WKY

Values represent means i SE, obtained 8 weeks after

initiation of diabetes or treatment (n = 4-6 pooled samples).
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Ventricular Action Potentials in Diabetic SHR:
Alterations prevented by Insulin or T3
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ABSTRACT
Diabetes imposes a pronounced cardiodepression in the
spontaneously hypertensive rat (SHR), which may be attributable, at
least in part, to attendant hypothyroidism.

A prolongation of the

ventricular action potential duration (APO) characteristic of either
diabetes or hypothyroidism, may be associated with this impairment.
Thyroid hormone treatment (in vivo) prevents mechanical and
biochemical deficits in hearts from diabetic SHR.

Chronic diabetes

(8 weeks) was chemically-induced in SHR and normotensive Wistar Kyoto
(WKY) rats by a single tail vein injection of streptozotocin (STZ; 45
mg/kg and 50 mg/kg, respectively).

A subgroup of diabetic SHR were

treated with daily injections of either insulin (10 U/kg/day) or
triiodothyronine (T ; 8-10 µg/kg/day).
3

Systolic arterial pressure

(SAP) and heart rate (HR) were recorded in vivo, before and 8 weeks
after STZ injections.

As expected,

diabet~s

lowered HR in both the SHR and WKY rats.

reduced SAP in SHR and

Either insulin or T
3

treatment of diabetic SHR prevented the drop in SAP and HR.

Absolute

left ventricular hypertrophy as assessed by the ratio of left to
right ventricular weights, was reversed by diabetes in SHR.

The

reversal was partially prevented by insulin, but not by T ,
3
treatment. Diabetes prolonged APO to the same extent in SHR
ventricular muscle as it did in WKY muscle, and these effects were
independent of changes in resting membrane potential, action
potential amplitude or rate of rise of the upstroke (Vmax).
Hypertrophy alone had no effect on APO, since this measurement was
the same in both nondiabetic SHR and nondiabetic WKY rats.

Thyroid

hormone treatment was as effective as insulin was in preventing the
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diabetes-induced changes of APO in SHR papillary muscle.

These data

suggest that prolongation of APO of ventricular muscle caused by
chronic, untreated diabetes is not affected by left ventricular
hypertrophy.

Furthermore, the data provide additional support that

the attending hypothyroidism is functionally significant in the
diabetic cardiomyopathy of SHR.
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INTRODUCTION
Hypertrophy may predispose the myocardium to the adverse effects
of diabetes.

Both clinical and experimental evidence indicate that

cardiomyopathies are more severe and perhaps more ' frequent when these
pathological conditions coexist (7, 15, 30).

Experimental studies

further show that mechanical, biochemical and morphological indices
of cardiac function are more severely impaired in diabetic
hypertensive rats than in animals with either disease alone (11, 12,
16, 18, 42, 57).

A hypothyroid state is often associated with poorly controlled
diabetes (40).

In addition to low serum thyroid hormone levels,

diabetes impairs peripheral T to T conversion, tissue T uptake,
4
3
3
and both affinity and density of nuclear T receptors (5, 8). The
3
influences of attendant hypothyroidism on the cardiovascular system
may be difficult to distinguish from those of diabetes.

Indeed,

certain cardiovascular manifestations of experimental diabetes, such
as the bradycardia, may be entirely attributable to the impaired
thyroid state (54).

The effectiveness of thyroid hormone treatment

on the progression of diabetic cardiomyopathies are not consistent
(22, 53) but may be more apparent in the presence of left ventricular
hypertrophy (11, 12).

Recently we have shown that the functional

impairments in diabetic spontaneously hypertensive rat (SHR) hearts
can be prevented by treating animals with either insulin or
triiodothyronine (T 3; 11). Treatment of SHR with T3 also prevented
the diabetes-induced depressions of sarcoplasmic reticular (SR)
calcium uptake and its mechanical correlate, ventricular relaxation
( 12).
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The relationship between the electrical properties of the
sarcolemrna and contractile events of cardiac muscle is well
characterized (for reviews see 19 and 36).

The cardiac action

potential (AP) configuration is similarly altered by the effects of
either hypertrophy, diabetes, or hypothyroidism (4, 9, 10, 17, 37,
47).

Prolongation of the cardiac AP is the most consistent

consequence common to all three abnormalities, and may be
functionally related to associated mechanical alterations which are
also characteristic of each condition.

A combination of these

disease states may have additive effects on ventricular transmembrane
potentials (18), as they seem to have on mechanical function (11,
12).

The central purpose of this study was to characterize the
influence of chronic, untreated diabetes on the configuration of the
papillary muscle AP in SHR and normotensive WKY rats.

Additional

aims included the assessment of the effectiveness of T3 treatment,
compared to that of insulin therapy, on ventricular electrophysiology
in diabetic SHR.

The results show that diabetes prolongs the cardiac

AP to the same extent in hypertrophic and nonhypertrophic papillary
muscle.

Furthermore, T treatment is as effective as insulin in
3
preventing the diabetes-induced AP prolongation.
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METHODS
Animal Groups.

Male spontaneously hypertensive rats (SHR) and Wistar

Kyoto (WKY) rats were purchased from Charles River Breeding
Laboratories (Wilmington, MA), then housed communally according to
strain, and fed ad libitum.

When the animals were 15 weeks of age,

they were weight matched and assigned to either nondiabetic or
diabetic groups.

Diabetes was induced by a single tail vein

injection of streptozotocin (STZ; Sigma Chemical Co., St. Louis, MO)
in lightly etherized animals.

The dose of STZ was adjusted for each

strain in order to induce comparable degrees of diabetes as indexed
by serum glucose levels (12):
received 50 mg/kg.

SHR, received 45 mg/kg, and WKY

The STZ was dissolved in citrate buffer (0.1 Mat

pH 4.5) just prior to use.

The nondiabetic animals were also

etherized and given comparable volumes of citrate buffer alone.
Glucose appeared in the urine (DIASTIX) of all STZ treated animals.
All animals were sacrificed eight weeks after the tail vein
injections.
The diabetic SHR were divided into three subgroups corresponding
to specific treatment regimes which were initiated three days after
the STZ injection.

One subgroup of diabetic SHR was treated with

protamine zinc insulin (I; Eli Lilly Co., Indianapolis, IN), 10
U/kg/day sc, administered once each day at 1600 hrs.

The second

subgroup of diabetic SHR was given a single daily injection of
triiodothyronine (T ; Sigma) 8-10 ug/kg/day sc (also at 1600 hrs).
3
After 6 weeks of treatment, the T dose was reduced from 10 ug/kg/day
3
to 8 ug/kg/day in order to avoid the development of T -induced
3
tachycardia (11). This dose of T3 was selected according to its
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ability to just prevent the progression of bradycardia during the 8
week period of diabetes (11, 42).

The third subgroup of diabetic

SHR

remained untreated for the entire 8 week period.
In Vivo Measurements.

Systolic arterial pressure (SAP), heart rate

(HR) and body weight (BW) were measured prior to the STZ injections,
and then eight weeks subsequently.

SAP was monitored continually

until three or more consistent measurements were observed, using a
standard tail-cuff sphygmomanometer contained in a temperature
controlled chamber (34°C).

HR was also monitored with the tail-cuff

apparatus, before and after the SAP recordings.

These measurements

were obtained prior to the daily T or insulin injections.
3
Intracellular Recordings.

Eight weeks following the tail vein

injections, all animals were rapidly decapitated, the hearts were
quickly excised and a papillary muscle was removed and prepared for
intracellular recordings.

A papillary muscle with an origin on the

left ventricular outer wall was isolated and superfused with
nonrecirculating Krebs-Henseleit buffer maintained at 34°c.
buffer composition was (mM);

The

120 NaCl, 5.6 KCl, 0.65 Mgso , 1.21
4

NaH Po , 25 NaHco , 2.4 CaC1 , 0.2 EDTA and 10 glucose (pH 7.4 when
2 4
3
2
warmed and gassed with 95% o and 5% co ). In order to minimize the
2
2
degree of contraction during electrical stimulation, muscles were
loosely anchored to the base of the preparation chamber.

The buffer

capacity of the chamber was 8 ml and the flow rate through the
chamber was maintained at approximately 3 ml/min.

Each muscle

preparation was allowed to equilibrate in buffer for 30 min prior to
recording membrane potentials.

A bipolar, silver wire suction

electrode was used with a Grass SD9 stimulator (Grass Instruments,
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Quincy, MA) to evoke cardiac action potentials at a frequency of 1
Hz.

Stimulus intensities were set just above threshold voltages with

square wave pulses of 0.5 ms duration.
placed at the apical end of the muscle .

The stimulating electrode was
Standard intracellular

electrodes were filled with 3 M KCl and connected to a DC
preamplifier (Model SVC 2000, WPI, New Haven, CT).

Transmembrane

potentials were monitored continuously on a storage oscilloscope
(Model 5103N, Tektronix, Beaverton, OR), and simultaneously monitored
and stored, for off-line analysis, in an IBM PCII, using A/D
conversion hardware (Data Translation, Marlborough, MA) and ASYST
software (Macmillan Software Co, New York, NY).

The sampling rate of

the A/D conversion was 1.25 µs, of which the digitized data were
averaged, sampled and stored every 1 ms.

Data acquisition was

synchronized by externally triggering A/D conversion through the
stimulator.

For each muscle fiber sampled, 4-5 action potentials

were recorded, and an average of 7 muscle fibers were sampled from
each animal.
AP Configuration Analysis.

The resting membrane potential (RP) was

recorded and the action potential (AP) configuration was described
using the following indices;

AP amplitude (AMP), time course to

complete repolarization (AP duration at 10% (APDlO), 25\ (APD25), 50\
(APD50) and 75\ (APD75) repolarization).

The maximum rate of rise of

the depolarization (V max ) was determined by calculating the maximum
first derivative of the stored AP.
Heart Weight Ratios.

Prior to the removal of the papillary muscle,

the hearts were quickly blotted dry and the following wet weights
were obtained;

whole heart (HW), left ventricle (LV) including the
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septum, and right ventricle (RV).

The degree of ventricular

hypertrophy was assessed using these heart weights.
Statistical Analvses.

The effects of diabetes on SAP and HR within

and between each strain were assessed using a three-way analysis of
variance (ANOVA) with repeated measures.

These in vivo measurements

were also assessed in diabetic SHR treated with either insulin or T
3
by means of a two-way ANOVA with repeated measures. To evaluate the
treatment effects for all ex vivo measurements, similar statistical
designs were employed, but without a repeated measures factor.

The

membrane potential data presented for each experimental group
actually represent the average values from multiple samples within a
given muscle fiber, and multiple fibers within a given papillary
muscle.

Thus, sample sizes presented in Table 3 reflect the number

of animals within each experimental group, rather than the number of
individual fibers sampled.

Probability values of 0.05 or less were

considered sufficient to indicate significant differences between
group means.

Simple effects and Student Newman-Keuls multiple

comparisons tests were used to further evaluate significant F values.
The mean square error term(s) from the parent ANOVA were used for the
follow-up tests.
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RESULTS
Systolic Arterial Pressure and Heart Rate.

At 15 weeks of age (week

0 in Table 1), SHR were already hypertensive and tachycardic when
compared to WKY.

As previously reported, diabetes depressed systolic

arterial pressure (SAP) in SHR but not in WKY (42).

Either insulin

or T treatment prevented the depressor effects of diabetes in the
3
SHR.

Similarly, heart rate (HR) was also reduced in diabetic SHR,

and maintained at nondiabetic levels by either insulin or T
treatment.

3

Diabetes did not produced a bradycardia in the WKY.

Body and Heart Weights.

Diabetes reduced body weight (BW) and whole

heart weight (HW) in both the SHR and WKY strains (Table 2).

Insulin

treatment prevented this BW loss, but only partially prevented
diabetes-induced HW loss.
or HW in diabetic SHR.

Treatment with T did not influence the BW
3

Absolute left ventricular hypertrophy

(LV/RV), but not relative ventricular hypertrophy (LV/BW) was
apparent in the hypertensive SHR when compared to the normotensive
WKY.

Diabetes decreased LV/RV in SHR, without altering LV/BW.

Insulin treatment, unlike T treatment, partially prevented the
3
diabetes-induced reversal of LV/RV ratio in SHR. Diabetes had no
effect on ventricular weight ratios in WKY.
Cardiac Action Potentials.

The membrane potentials of papillary

muscles from nondiabetic SHR were quantitatively similar to those of
nondiabetic WKY muscles (Figure 1, Table 3 and Table 4).

There were

no significant strain-dependent differences with regard to resting
membrane potential (RP), action potential (AP) amplitude (AMP), and
AP duration to 10% repolarization (APDlO), 25% repolarization
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(APD25), 50\ repolarization (APD50) and 75\ repolarization (APD75),
or V
max
Diabetes prolonged the APO to the same extent in both SHR and
WKY papillary muscles (Figure 1, Table 3 and Table 4).

This

prolongation of the AP was observed at all points sampled after peak
depolarization.

Diabetes-induced changes in AP configuration were

independent of changes in RP, AMP or V
max
Treating diabetic SHR with either insulin or T in vivo
3
completely prevented the changes in AP configuration in vitro (Figure
1 and Table 3).

The RP, AMP and V
of muscles from insulin-treated
max

and T -treated diabetic SHR were the same as those from nondiabetic
3
SHR.
T treatment as well as insulin treatment completely prevented
3
the diabetes-induced increases in APO at all stages of
repolarization.
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DISCUSSION
The results of this study show that diabetes prolongs the
cardiac action potential (AP) in SHR and in WKY papillary muscles,
and that the AP duration (APO) of nondiabetic SHR and WKY rat muscle
were not different (Table 3).

The results provide additional

evidence that the 23 week-old SHR is in the adaptive stage of
hypertrophy (39), in which the ventricular muscle is electrically,
mechanically (42) and, in part, biochemically (12) normal.

Volkmann

et al. (56) described similar results when comparing membrane
potentials from 15 week-old SHR and WKY.

Our data also show that the

adverse effect of untreated diabetes on AP configuration in both
hypertrophic and nonhypertrophic muscle are quantitatively similar.
A prolonged APO is characteristic of diabetic, hypothyroid and
compromised hypertrophic ventricular muscle (9, 10, 17, 27, 37).
cellular basis for the increased APO is not yet known.

The

It has been

suggested that the net inward current during the plateau phase is
increased with hypothyroidism (20) or hypertrophy (33), perhaps due
to a decrease in outward Kt current.

An increased density of

voltage-dependent calcium channels in hypothyroid rat hearts (26)
could also explain these findings.

Furthermore, the time course of

the AP of hypertrophic muscle appears to be extended by a depressed
rate of inactivation of the slow inward current, when compared to
normal muscle cells (4, 33).

It is still not clear whether the

underlying mechanisms which prolong the AP in cardiac muscle of
diabetic, hypertensive and hypothyroid animals have a common ionic
basis.
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The influx of calcium during the cardiac AP probably increases
with extended depolarization times, regardless of the mechanism of
APD prolongation.

A number of investigators have linked depressed

mechanical activity with increased intracellular calcium
concentrations (1, 4, 37), since an excess of free intracellular
calcium can be toxic to the cell (13).

Whether calcium overload

exists with diabetes is still a source of debate (13, 29, 48);
nonetheless, abnormal intracellular calcium handling is a common
phenomenon among diabetic, hypertrophic and hypothyroid cardiac
tissue (21, 38, 43).
Increased duration of the cardiac AP is often associated with
disrupted mechanical activity in diabetic (17, 37) and hypertrophic
myocardium (4, 10, 25, 28, 55).

The results of this study are

consistent with the pronounced mechanical deficits imposed by
diabetes on the intact ventricle of SHR (11, 12, 42, 45, 57).
Diabetes reduces maximum left ventricular (LV) pressure and rates of
contraction and relaxation in the isolated working SHR heart (11,
42).

It also depresses a biochemical correlate of relaxation, the

rate and extent of calcium uptake by the sarcoplasmic reticulum (SR)
in SHR (12).

Prolongation of the AP is also evident of renovascular

hypertensive (RVH) rat in papillary muscle (3) and is exacerbated by
superimposed diabetes (18).

Diabetes also impairs isometric

relaxation of these papillary muscles to a greater extent than in
nonhypertrophic muscles (17, 18).
Configurational changes in the AP alone caused by diabetes may
not be sufficient to influence contractile events in the heart.

Our

data also show that diabetes prolongs the AP to the same extent in
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SHR and WKY papillary muscles (Table 3).

While diabetes depresses

cardiac function in the SHR (e.g., LV pressure and SR Ca

2t

uptake),

it has no effect on the function of the WKY heart (11, 12, 57).
Conversely, other authors have reported mechanical changes in heart
muscle imposed by different pathological conditions (including
hypertrophy and hypothyroidism) without concomitant alterations in
the AP (32, 41, 51, 56).

Collectively, these data must call into

question the direct association of disrupted membrane potentials and
mechanical function.

The evidence obtained from the WKY strain

suggests that intracellular events subsequent to the AP (e.g., SR
Ca

2t

uptake and perhaps myosin ATPase activity) are the primary

determinants of alterations in myocardial performance affected by
diabetes in the SHR strain.
Changes in APO due to either diabetes, hypothyroidism, or
hypertrophy are generally independent of resting membrane potential
(RP), AP amplitude (AMP) or rate of depolarization (Vmax; 3, 9, 10,
17, 20, 47).

Neither diabetes nor hypertrophy affected RP, AMP or

V
(Table 4);
max

however, the values for these measurements differ

somewhat from previously published data.

A papillary muscle RP

typically ranges from -70 to -78 mV (17, 47, 56) yet the average RP
for all groups in our study is approximately -65 mV (Table 4).

The

RP is primarily dependent on the activity of sarcolemma (SL) Nat/Kt
ATPase, which is highly sensitive to temperature and metabolic
disturbances (e.g., hypoxia).

Sauviat and Feuvray (47) and Fein et

al. (17) reported RP values of -60 mV from papillary muscle
superfused with buffer below 30°c.

Exposure to either hypoxic

conditions or ouabain inhibits Nat/Kt ATPase activity and reduces
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papillary muscle RP (2, 17).

A reduced RP may partially inactivate

the voltage-dependent Na+ channels which are primarily responsible
for the initial depolarization.

Often V
is used as an indirect
max
index of Na+ channel conductance (50). Accordingly, low temperatures

and metabolic inhibitors reduce V , and this might help explain a
max
nearly 5-fold decrease in our V
values when compared to published
max
data. Decreased Nat/Kt ATPase activity may not, however, explain all
of our discrepant results.

Normal SHR (22 week-old) have

significantly lower SL Nat/Kt ATPase and reduced ouabain sensitivity
than do SL membranes from WKY (35), but do not differ with respect to
either RP or V
(Table 4; 56). The APO of hypoxic muscle is
max
characteristically shorter than the APO of normal muscle (24).
Despite the deviations between our data and those of others, the APO
of nondiabetic SHR and WKY are quantitatively similar to other
published values (56).
Treatment with either insulin or thyroid hormone prevents the
diabetes-induced changes in AP configuration of SHR papillary muscle.
The effectiveness of insulin treatment on the electrophysiological
properties of diabetic SHR hearts is not surprising, since most of
the in vivo metabolic changes are also preventable (Tables 1 and 2).
However, until recently the hypothyroidism attending diabetes was
thought to have only a minimal impact on cardiac mechanical function
in the diabetic rat (6, 14, 21, 23, 53, 54).

However LeGaye et al.

(34) reported that treatment of diabetic normotensive rats with T3
partially prevents the prolongation of atrial muscle AP.

Our

findings indicate that T completely prevents the delayed
3
repolarization of papillary muscle in diabetic SHR. These data,

-102-

coupled with similar findings on mechanical and biochemical indices
of function (11, 12, 42), strongly suggest that the thyroid hormone
deficit is responsible, at least in part, for the diabetes-induced
effects on SHR heart function.

Preliminary results also show that T
3
treatment of diabetic RVH can prevent cardiac functional impairments
in this model of hypertensive diabetic cardiomyopathy as well
(unpublished observations).

Thus, the presence of preexisting

hypertrophy may influence myocardial dependence on thyroid hormone
during the diabetic state.
The cellular mechanisms by which insulin and T affect cardiac
3
excitation contraction coupling are not understood. Insulin may
influence cardiac function by improving metabolic activities;

for

example by increasing glucose availability, reducing fatty acid (FA)
accumulation and protein wasting, or by changing sympathetic nerve
activity (13).

Even though a single daily injection of insulin does

not always adequately control the serum hyperglycemia or BW loss in
diabetic SHR, the hormone treatment is sufficient to maintain normal
heart function (11).

Rubinstein et al. (46), and more recently

Rodrigues et al. (44), have also demonstrated that incomplete insulin
therapy restores cardiac mechanical activity without fully correcting
all metabolic changes associated with diabetes in the rat.
Similarly, T3 treatment of diabetic SHR does not control the
hyperglycemia or BW loss, yet effectively maintains normal cardiac
performance ex vivo (Table 2, Table 3 and Figure l; 11, 12).

It is

possible that a portion of insulin's actions is secondary to that of
thyroid hormone (52), since insulin treatment also prevents the
attendant hypothyroidism of diabetes (11).
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The AP configuration of diabetic SHR papillary muscle may be
influenced directly or indirectly by T treatment. For example,
3
thyroid hormone can decrease the density of ca 2+ channels in the rat
ventricle (26), which would reduce the net inward current and enhance
rates of repolarization.

· 2+

By preventing depressed rates of Ca

uptake by the SR, T treatment may reduce a transient inward current
3
activated by intracellular ca 2+ (12). Diabetes-induced increase of
intracellular and membrane-bound FA (13) may disrupt the electrical
activity of the heart, particularly when glucose is not an available
fuel source.

Katz and Messineo (31) demonstrated that the

accumulation of FA can influence the AP configuration when glucose
availability is restricted.

T3 treatment, known to increase glucose

uptake and utilization by cardiac muscle (49), may prevent this
impairment.
To our knowledge, this is the first study showing that diabetes
induces a prolongation of the AP in papillary muscle of the SHR, and
that in vivo T treatment is as effective as insulin treatment in
3
preventing this prolongation.

T treatment in diabetic SHR not only
3

prevents the impairments in cardiac electrophysiology, but also those
relating to cardiac performance and a biochemical index of function
(11, 12).

Thus, thyroid hormone deficits may be an important

component in the etiology of diabetic cardiomyopathy in SHR.
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Table 1.

Systolic arterial pressure and heart rates of nondiabetic and
diabetic SHR and WKY rats.

SAP (mmHq)
Group

(nl

Week 0

HR (beats/min)

Week 8

Week 0

Week 8

llB.
Nondiabetic

( 7)

198 .±. 20y

196 .±. 17y

399 .±. 19y

418 .±. 27y

Diabetic

(7)

198 ±. 10

140 ±. 12*

401 ±. 25

298 ±. 27*

Diabetic + I

( 8)

194 ±. 24

185 ±. 22

381 ±. 27

378 ±. 31

Diabetic + T3

( 7)

189 .±. 16

201 .±. 12

383 .±. 26

438 .t 48

Nondiabetic

(6)

144 ±. 16

142 ±. 19

333 ±. 26

307 ±. 32

Diabetic

( 7)

141 ±. 16

134 ±. 18

328 ±. 20

283 ±. 24

m

Values represent means ±. SD, obtained 8 weeks after initiation of diabetes or
treatment.

SAP, systolic arterial pressure; HR, heart rate; I, protamine zinc

insulin; r , triiodothyronine.
3
~Significantly different from the nondiabetic group (within strain).
YSignificantly different from the nondiabetic WKY.
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Table 2.

Body and heart weights of nondiabetic and diabetic SHR and WKY rats.

Group

(n)

BW

HW

(g)

(mg)

LV/BW
(mg/g)

LV/RV
(mq/mg)

WR.
Nondiabetic

( 7)

338 .±. 21y

1.27 .±. 0.07

2.92 .±. 0.12

5.43 ± 0.46y

Diabetic

( 7)

195 ±. 25*

0.70 ±. 0.11*

2.60 ±. 0.48

4.22 ±. 0.32*

Diabetic + I

( 8)

327 ±. 19

1.15 ±. 0.08** 2.67 ±. 0.09

4.90 ±. 0.25**

Diabetic + T3

( 7)

187 .!. 12*

0.83 .!. 0.12** 3.12 ! 0.30

4.13 ! 0.29*

Nondiabetic

( 6)

385 ±. 21

1.38 ±. 0.25

2.57 ±. 4.25

3.84 ±. 0.52

Diabetic

( 7)

302 ±. 31*

1. 09 ±. 0.27*

2.56 ±. 0.64

3.93 ±. 0.32

m

Values represent means ±. SO, obtained 8 weeks after initiation of diabetes or
treatment.

BW, body weight; HW, heart weight; LV, left ventricular weight; RV,

right ventricular weight; I, protamine zinc insulin; T , triiodothyronine.
3
*Significantly different from the nondiabetic group (within strain).
**Significantly different from the nondiabetic and diabetic groups (within
SHR).
YSignificantly different from the nondiabetic WKY.

-114-

Table 3.

Papillary muscle action potential duration of nondiabetic and
d iabetic SHR and WKY rats.

Group

(n)

APD50
(ms)

~

Nondiabetic

( 7)

12.2 .±. 1.5

16.5 .±. 1.8

24.8 ±. 2.2

39.5 ±. 2.6

Diabetic

( 7)

27.6 ±. 3.5*

39.0 ±. 3.7*

57.1 ±. 5.0*

91. 9 ±. 7.8*

Diabetic + I

( 8)

11.4 .±. 1. 2

15.1 ±. 2. 0

22.7 ±. 2.3

36.2 ±. 3.6

Diabetic + Tl

( 7)

14.0 .±. 2.0

18.6 .±. 2.3

26.5 .±. 2.8

40.3 .±. 4.1

Nondiabetic

(6)

8.2 ±. 2.0

11. 4 .±. 2 .1

17.2 .±. 2.7

28.5 .±. 3.4

Diabetic

( 7)

28.9 ±. 5.9*

37.9 ±. 7.1*

54.7 ±. 9.8*

84 . 0 ±. 13 .8*

m

Values represent means ±. SE, obtained 8 weeks after initiation of diabetes or
treatment.

Sample sizes reflect number of animals from which multiple fibers

(4-10) were sampled and averaged.

APD

-APD , action potential duration at
10
75
10\-75\ repolarization; I, protaaine zinc insulin; T , triiodothyronine.
3
*Significantly different from the nondiabetic group (within strain).
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Table 4.

Papillary muscle membrane potential characteristics of nondiabetic
and diabetic SHR and WKY rats.

Group

(n)

RP

AMP

Vmax

(-mV)

(mV)

(V/S)

~

Nondiabetic

(7)

65.4 ±. 1.4

79.0 ±. 2.5

28 ±. 2

Diabetic

( 7)

61. 8 ±. l. 4

82.9 ±. 3.8

22 ±. 3

Diabetic + I

( 8)

64.6 ±. 1.0

80.4 ±. 1. 5

27 ±. 2

Diabetic + T3

( 7)

64.9 .± 0.8

80.7 .± 1. 9

26 + 1

Nondiabetic

(6)

64.9 ±. 2.4

81.6 ±. 2.8

27 + 3

Diabetic

( 7)

65.2 ±. 2.0

84.l ±. l. 3

28 ±. 2

m

Values represent means ±. SE, obtained 8 weeks after initiation of diabetes or
treatment.

Sample sizes reflect number of animals from which multiple fibers

(4-10) were sampled and averaged.

RP, resting membrane potential; AMP, action

potential amplitude; Vmax, maximum rate of rise; I, protamine zinc insulin; r ,
3
triiodothyronine.

-116-

Figure 1:

Representative papillary muscle action potentials (AP).

(A) The AP were recorded from nondiabetic SHR (ND), diabetic SHR (D),
nondiabetic WKY (NOW) and diabetic WKY (OW), and (B) from T -treated
3
diabetic SHR (D+T 3) and insulin-treated diabetic SHR (D+I). The
individual AP were recorded from a single animal within each
experimental group and were chosen because they best represented the
average AP configuration as described in Table 3.
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GENERAL DISCUSSION
The results of this study can be summarized according to the
original aims and hypotheses as follows:
1) Untreated diabetes mellitus of 8 weeks duration caused a
pronounced deficit in mechanical performance of spontaneously
hypertensive rat (SHR).

The depressed function in diabetic SHR

hearts was not attributable to either malnutrition or a
nonspecific effect of the diabetogen streptozotocin.
hormone treatment (in vivo)

Thyroid

was nearly as effective as insulin

treatment was in preventing the diabetes-induced
cardiodepression in SHR.
2) Diabetes impaired left ventricular (LV) relaxation and
Ca

2+

uptake by the sarcoplasmic reticulum (SR) in the SHR but

not in the nonhypertensive Wistar Kyoto (WKY) rat.
3) Thyroid hormone treatment, like insulin, completely
prevented depressed rates of load-dependent relaxation and SR
Ca

2+

uptake in diabetic SHR hearts.

4) Diabetes prolonged ventricular action potential (AP) to the
same extent in SHR as it did in WKY rats, and the AP duration
(APO) was similar in both nondiabetic strains.
5) Either thyroid hormone or insulin treatment prevented the
APO changes associated with diabetes in SHR papillary muscle.
6) Chronic diabetes had the same cardiodepressive effects on
mechanical performance in the renovascular hypertensive (RVH)
rat as it had in the SHR (Appendix A).
7) Either thyroid hormone or insulin treatment prevented
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diabetes-induced mechanical impairments in RVH heart
performance.
Thus, these results support the central hypotheses of the study, with
the following exception:

The effects of chronic diabetes on APO of

SHR papillary muscle were not more pronounced than they were on the
APO of nonhypertrophic WKY muscle.
The preexisting hypertrophy, rather than the etiology of
hypertension, may be a primary factor influencing the exaggerated
effects of diabetes on cardiac performance of hypertensive rats.

The

SHR and RVH are two experimental models which have been used to
investigate the combined effects of diabetes and hypertrophy on
cardiac function.

Hypertension is induced in · the RVH by surgically

imposing elevated plasma renin activity (Goldblatt 1934).

The SHR

strain is genetically predisposed to elevated arterial pressures,
which is believed to stem, in part, from enhanced central sympathetic
activity (Yamori 1975) and is characterized by normal or below normal
plasma renin activity (Sonkodi and Abraham 1988).

One obvious common

denominator of the RVH and SHR models of hypertension is the presence
of LV hypertrophy.

The presence of LV hypertrophy alone is not

always associated with impaired cardiac mechanical performance
(Pfeffer et al. 1979; Capasso et al. 1986; Rodgers et al. 1986).

The

results of this study provide additional evidence that cardiac
function in 23 week-old SHR is still within the adaptive phase of
hypertrophy.

Cardiac mechanical performance is also normal after 12

weeks of imposed hypertension in 23 week-old RVH (Appendix A).
However, when diabetes coexists with LV hypertrophy (in either SHR or
RVH), LV contraction and relaxation of perfused hearts are depressed
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more than when diabetes is imposed on nonhypertrophic hearts (Rodgers
1986; Rodrigues and HcNeill 1986; Davidoff and Rodgers; Davidoff et
al.; Appendix A).

Isometric relaxation is also prolonged in

papillary muscles from diabetic RVH (Fein et al. 1984).

The effects

of diabetes on cardiac function in hypertensive rats is independent
of either sustained hypertension or LV hypertrophy.

Diabetes

depresses SAP in SHR without significantly changing SAP in RVH
(Rodgers 1986; Davidoff and Rodgers: Appendix A).

The depressor

effects of diabetes is SHR in not always correlated with reversal of
LV hypertrophy (Rodgers 1986; Davidoff and Rodgers; Davidoff et al.;
Davidoff and Rodgers).

Diabetes, however, consistently impairs

mechanical performance in both SHR and RVH but it has no effect on
cardiac function in nonhypertensive, nonhypertrophic WKY rats.
Diabetes depresses LV pressure generation in nonhypertensive
Sprague-Dawley rat hearts, but the magnitude of diabetes-induced
effects are markedly greater in SHR (Rodgers 1986).

Therefore, the

key characteristic, which accounts for the exacerbation of the
cardiodepressant effects of diabetes, seems to be preexisiting LV
hypertrophy.
The predisposition of LV hypertrophy on cardiodepressive effects
of

diabetes involves the reticular elements of the myocyte.

A

biochemical defect often found to be characteristic of diabetic
myocardium is a depressed rate of ca 2+ sequestration by SR microsomes
(Dhalla et al. 1985).

A reduced rate of SR Ca 2+ uptake is generally

associated with impaired load-dependent relaxation (Brutsaert et al.
1980; Bers 1985; see also discussion in Davidoff et al.).

Proposed

mechanisms include reductions in either the density or the activity

-121-

of Ca

2+

-Mg

2+

ATPase {Penpargkul et al. 1981; Ganguly et al. 1983;

Schaffer et al. 1989), alterations in membrane lipid profiles
(Lopaschuk et al. 1983; Ganguly et al. 1983; Kim and LaBella 1988),
or changes in the degree of membrane phosphorylation (Kranias et al.
1988).

Until now, studies of this kind have been restricted to

nonhypertensive, nonhypertrophic models.

The data presented in this

study suggest, however, _that the adverse effects of diabetes on left
ventricular SR ca 2+ uptake activity are exacerbated by preexisting
hypertrophy.

Thus, diabetes of equal duration and severity - as

measured by serum glucose and insulin levels - depresses SR ca 2+
uptake of SHR left ventricles, but has no effect in the
nonhypertensive WKY strain.

These results extend those of earlier

studies which had demonstrated that the detrimental effects of
chronic diabetes on various indices of cardiac mechanical activity
are more pronounced in hypertrophic than in nonhypertrophic
ventricles of both the SHR and RVH models (Fein et al 1984; Rodrigues
and McNeill 1986; Rodgers 1986; Davidoff and Rodgers; Appendix A).
Increased duration of the cardiac AP may be linked to disrupted
mechanical activity in both diabetic {Fein et al. 1983; Nordin et al.
1985) and hypertrophic myocardium {Gulch et al. 1979; Heller and
Stauffer 1981; Aronson and Keung 1983; Thollon et al. 1985; Capasso
et al. 1986).

There is a considerable amount of evidence to suggest

that calcium metabolism is abnormal in either diabetic or
hypertrophic myocardium.

Heart muscle from both disease states may

exhibit increased frequency of afterdepolarizations and triggered
activity {Fein et al. 1983; Nordin et al. 1985), altered SR or
sarcolemmal calcium fluxes (Penpargkul et al. 1980; Limas and Cohen
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1979; Rodgers et al. 1986; Andrawis et al. 1988; Nakanishi et al.
1989; Davidoff et al.), and beneficial responses to calcium channel
blockers (Afzal et al. 1988, 1989).

In many of these studies,

depressed mechanical activity of muscle have been linked to elevated
intracellular calcium concentrations (Aronson and Keung 1983; Nordin
et al. 1985; Afzal et al . 1988; Afzal et al. 1989), which in turn is
assumed to be toxic to the cell (Dhalla et al. 1985; Andrawis et al.
1988).

The influx of calcium during the cardiac AP probably

increases with delayed repolarization and may contribute to changes
in metabolism and mechanical functions.

It has been suggested that

the net inward current during the plateau phase is increased in some
models of hypertrophy (Kleiman and Houser 1988), is perhaps due to a
decrease in outward Kt current .

The time course of the AP of

hypertrophic muscle appears to be prolonged by a depressed rate of
inactivation of the slow inward (Ca 2+J current, when compared to
normal muscle cells (Aronson and Keung 1983; Kleiman and Houser
1988).

It is still not clear, however, whether the underlying

mechanisms which prolong the AP in cardiac muscle of both diabetic
and hypertensive animals have a common ionic basis.
The cardiac APD in several hypertensive animal models is
significantly prolonged relative to that in normotensive animals.
Aortic stenosis, renal artery constriction and chemically-induced
hypertension promote ventricular hypertrophy and changes in AP
configuration to varying degrees (Aronson 1980; Heller and Stauffer
1981; Thollon et al. 1985; Capasso et al. 1986; Nordin et al. 1989).
The hypertrophic papillary muscle of SHR (Kawamura et al. 1976) does
not, however, exhibit longer repolarization times when compared to
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the nonhypertrophic WKY (Davidoff and Rodgers).

While there were no

statistical differences between APO of nondiabetic SHR and WKY
papillary muscle in this study, there was an apparent trend toward
higher APO values in SHR.
statistical differences.

Larger samples sizes may support
Hayashi and Shibata (1974) recorded

ventricular AP from Langendorf perfused hearts of SHR and WKY.

It is

not clear from their data whether the average APDlOO is significantly
greater for SHR than for WKY (mean (ms) ±SE (n=5), 104.0 ± 3.1 and
93.9 i 3.2, respectively).

Volkmann et al. (1989) recently reported

APD80 values for papillary muscle in SHR and WKY of 37.7 ± 3.0 and
33.9 ± 1.8, respectively (meant SE, n= 9 and 10).

The differences

in APO between SHR and WKY are not as apparent as they are in other
models of hypertrophy, but whether the discrepancies are related to
the genetic strain, etiology or duration of hypertrophy, or other
factors, remain to be tested.
These results suggest that alterations in electrophysiological
characteristics of ventricular muscle may contribute to the etiology
of diabetic cardiomyopathy in SHR.

The data in this study also show,

however, that diabetes prolongs the AP to the same extent in SHR and
WKY papillary muscles, but depresses cardiac function only in the SHR
(e.g., LV pressure and SR ca 2+ uptake; Yammamoto and Nakai 1988;
Davidoff and Rodgers; Davidoff et al.).

In other normotensive rat

strains, however, diabetes prolongs APO and impairs mechanical
function (Fein et al. 1980; Fein et al. 1983; Sauviat and Feuvray
1985).

While the dissociation of electrical and mechanical events is

not common, it is not without precedent.

Indices of isometric

contraction but not AP configuration of rat papillary muscles were
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affected by chemically-induced thyroidectomy (6-7 weeks) and
thyrotoxic doses of T3 (2 weeks; Poggesi et al. 1987).

An increase

in isometric tension in SHR papillary muscle did not correspond to a
change in AP configuration

when compared to these measurements in

WKY muscle (Volkmann et al. 1989).

Collectively, these data must

call into question the direct association of disrupted membrane
potentials and mechanical function.

The evidence obtained from the

WKY strain suggests that intracellular events subsequent to the AP
(e.g., SR Ca

2+

uptake and perhaps myosin ATPase activity) are the

primary determinants of alterations in myocardial performance
affected by diabetes in both hypertensive and normotensive rat
strains.
The mechanism responsible for the apparent interaction between
diabetes and LV hypertrophy with respect to cardiac function remains
a matter of speculation.

Metabolic derangements in the diabetic

heart include decreases in lipolytic activity, fatty acid (FA)
oxidation and glucose utilization (Paulson and Crass 1982; Vary and
Neely 1982; Kobayashi and Neely 1983; Dhalla et al. 1985).

These in

turn are linked to changes in energy substrate availability, membrane
integrity and function in the heart (Dhalla et al. 1985).
Hypertrophy may exacerbate these metabolic effects.

Like diabetes,

LV hypertrophy is associated with alterations in lipid metabolism
(Reibel et al. 1983; Reibel et al. 1987; Fujii et al. 1988; Rodrigues
et al. 1988), restricted fuel source availability (Savabi 1988;
Wexler et al. 1988), and changes in sarcolemmal (SL) ion transport
(Lee et al. 1983; Nakanishi et al 1989).

Hypertrophic muscle may

undergo compensatory intracellular changes to accommodate elevated
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workloads and reduced coronary reserves (Shimamoto et al. 1982; Tubau
et al. 1989).

For example, an increase demand for FA oxidation, as

the primary fuel source, may be met by increased myocardial carnitine
content (Foster et al. 1985; Reibel et al. 1987). · Changes in SL ion
pump activities may enhance intracellular ca 2+ concentration and
augment myocardial contractility.

These and other cellular

mechanisms may combine to predispose the hypertrophic ventricle to
membrane-disrupting effects of diabetes.
A low thyroid state might contribute significantly to changes in
cardiac performance of diabetic SHR.

Methimazole treatment of SHR

causes a depression in heart performance ex vivo that is
qualitatively similar to the effects of diabetes, though lesser in
magnitude (Rodgers 1986).

These results were confirmed in a later

study of the effects of surgical thyroidectomy on cardiac function in
SHR (Rodgers and McNeill 1986).

Based on these observations, it was

expected that triiodothyronine (T ) treatment of diabetic SHR might
3
reduce the magnitude of the subsequent impairment in mechanical
function.

It was somewhat

~urprising

that T3 was almost as effective

as insulin was in preventing the depressions in measurements of heart
function, including pressure generation, rates of contraction and
relaxation and stroke work.
The present results differ to some extent from previous reports
of the effects of T treatment on cardiac function and hemodynamic'
3
measurements in normotensive rat strains. Higher doses of T3 (25-30
µg/kg/day), administered to diabetic Wistar rats for 6 weeks, failed
to prevent the cardiac functional impairments (Tahiliani and McNeil!
1984), but when given to diabetic Sprague-Dawley (SD) rats for only 5
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days, restored mechanical indices of cardiac function to normal
(Garber et al 1983).

In the latter study, lower doses of T
3
(considered to be more appropriate for replacement therapy of
hypothyroidism) were not completely effective.

In a recent report,

Barbee et al. (1988) found that approximately 4 µg T per rat per day
3
for 3 weeks (by subcutaneous pellet implant) did not improve
performance of unpaced hearts from diabetic SD rats.

However, these

investigators also failed to demonstrate any effect of diabetes on
paced heart function.

For the present studies, the dose of T was
3
selected according to its ability to restore to normal the depressed
heart rate (HR) in vivo, an index which is a sensitive indirect
indicator of thyroid status.

This turned out to be about 2-3 fold

greater than "physiologic" replacement doses in nonhypertensive rat
strains (Dillmann 1982).

The T dose used herein did not appear,
3

however, to impose a hyperthyroid condition in diabetic SHR.
conclusion is based on the following:

This

1) The dose used did not

elevate serum T3 levels above normal, when measured at the same time
point after injection, in either the diabetic or nondiabetic SHR
groups (Davidoff and Rodgers);

2) The same dose given to nondiabetic

SHR had no effect on heart and body weights, or on SAP or HR in vivo;
and 3) T treatment of nondiabetic SHR had no effect on any of the
3
indices of cardiac performance ex vivo.

Although T treatment
3

reduced body weights of the diabetic SHR, it had no effect on this
measurement in the nondiabetic control group.
The difference in the effectiveness of T in diabetic SHR
3
compared to normotensive rats are probably related to the elevated
arterial pressure of SHR, and not to differences related specifically
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to the genetic strain.

Treatment with T prevents the
3

cardiodepression in diabetic RVH as well as in diabetic SHR (Appendix
A).

It is possible that hypertrophy, stimulated by elevated arterial

pressure in both models, may increase cardiac susceptibility to a
number of stresses including those imposed by diabetes (Factor et al.
1981; Rodgers 1986; Rodrigues and McNeill 1986), hypothyroidism
(Rodgers et al. 1986), or ischemia (Mochizuki et al. 1986).

This

suggests that the hypothyroidism accompanying diabetes has a more
profound cardiovascular effect in animals with elevated arterial
pressure, and that hypertrophied myocardium may be functionally more
dependent upon thyroid status than is nonhypertrophic heart muscle.
There are a number of mechanisms by which T therapy might
3
effectively prevent the cardiac functional impairments of diabetes,
especially in hypertrophic heart muscle.

Thyroid hormone may relieve

some of the metabolic stresses by increasing myocardial utilization
of FA and decreasing FA accumulation (Markin et al. 1983; Muller and
Seitz 1984a; Tanaka et al. 1985).

Enhancing plasma lipid clearance

with methionine treatment, for instances, improves cardiac
performance in diabetic Wistar rats (Heyliger et al 1986).

The

vasodilator hydralazine reduces serum lipids in diabetic Wistars and
improves cardiac function of isolated working hearts (Rodrigues et
al. 1986).

Interestingly, hydralazine treatment also corrects the

hypothyroid state in these diabetic rats.

Other actions of thyroid

hormone include stimulation of glucose uptake and cellular metabolism
(Muller and Seitz 1984b; Tanaka et al. 1985; Gordon et al. 1986;
Segal 1989).

T directly stimulates glucose uptake in several rat
3
tissues including the heart, by enhancing the activity of the plasma
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membrane transport mechanism (Segal 1989).

Treatment of diabetic SHR

and RVH with T may increase the availability of glucose and lipids
3
as energy substrates and reduce FA accumulation, which would help to
account for the improved cardiac function.

This and other related

metabolic actions may be more crucial, and more apparent, ·against a
background of high workloads and associated metabolic demand .
A common biochemical change observed in hearts from either
diabetic, hypertensive or hypothyroid animals is depressed SR ca 2+
uptake, which correlates with impaired myocardial relaxation (Suko
1973; Dhalla et al. 1985; Rodgers et al. 1986). Thyroid hormone
treatment does not restore SR ca 2+ uptake or LV function in diabetic
normotensive rats (Ganguly et al. 1983; Tahiliani and McNeil! 1984),
yet is completely effective on diabetic hypertensive muscle (Davidoff
et al.).

The presence of hypertrophy may account for the

differential effects of diabetes and T treatment on cardiac
3
function, in part because of alterations in lipid metabolism (see
2+
2+
above). The acute effects of T on Ca -Mg
ATPases are profoundly
3
influenced by the lipid environment (Galo et al. 1981).

Because

hypertrophy (Petkov et al. 1988), hypothyroidism (Galo et al. 1981)
and diabetes (Gudbjarason et al. 1987) all affect membrane lipid
composition, it seems reasonable to hypothesize that different
combinations of these pathophysiologic conditions will have variable
influences on the subsequent effects of T administration. In
3
normotensive rats, myoinositol coadministration increases the
therapeutic efficacy of T in diabetic cardiomyopathy (Xiang et al.
3
1988) . Fatty acyl esters of carnitine may be especially important.
Enhanced incorporation of long chain acyl carnitines (LCAC) into the
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SR membrane is correlated with depressed rates of Ca 2+ uptake in
diabetes (Lopaschuk et al. 1983) and r

3

treatment decreases LCAC

levels in SR membranes (Black et al. 1988).

Another potential

mechanism undoubtedly involves the regulation of SR Ca 2+ pump
Chronically, r

activity by thyroid hormone.
rate of SR Ca

2+

3

probably increases the

.
2+
2+
uptake by accelerating the synthesis of Ca -Mg

ATPase enzyme molecules.

Hypothyroidism has opposite effects on

these measurements (Rohrer and Dillmann 1988).
Disruptions in myocardial excitation-contraction coupling
characteristic of diabetes, hypertension and hypothyroidism (Fein et
al 1983; Nordin et al. 1985; Capasso et al 1986) include prolongation
of the cardiac AP.

T treatment prevents diabetes-induced
3

alterations in SHR cardiac AP, and thus normalizes the first step
leading to mechanical activity.

The AP configuration of diabetic SHR

papillary muscle may be influenced directly or indirectly by T
3
treatment.

For example, thyroid hormone can decrease the . density of

2
ca + channels in the rat ventricle (Hawthorn et al. 1988), which
would reduce the net inward current and enhance rates of
repolarization.

Similarly, r

3

treatment may inhibit a transient

inward current activated by intracellular ca 2+, by restoring normal
rates of SR ca 2+ uptake (T

3

prevents depression of ca 2+ uptake by the

SR in diabetic SHR; Davidoff et al.).

Diabetes-induced increase of

FA (Dhalla et al. 1985) may disrupt the electrical activity of the
heart, particularly when glucose is not an available fuel source.
Katz and Messineo (1981) demonstrated that the accumulation of FA can
influence the AP configuration when glucose availability is
restricted.

T treatment, shown to increase glucose uptake and
3
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utilization by cardiac muscle (Segal 1989), may prevent this
impairment.
Another common manifestation of diabetes, hypertrophy and
hypothyroidism in rat ventricular muscle is a shift from the
predominant v1 to the v myosin isozyme (Malhotra et al. 1981;
3
Mercardier et al. 1981; Dillmann 1982; Garber et al. 1983; Morkin et
al 1983; Rupp and Jacob 1986; Schaffer et al. 1989).

By extension,

the effects of hypertension and diabetes (with or without
hypothyroidism) on myosin isozyme profiles may be additive, but this
hypothesis has not been tested.

Thyroid hormone treatment in animals

with a normally higher distribution of

v3

than

v1

promotes a shift to

the more active v form (Morkin et al. 1983; Williams and Ianuzzo
1
1988). Garber et al. (1983) were able to prevent the
diabetes-induced

v3

shift with T treatment in SD rats. T
3
3
administration to diabetic SHR and RVH may also change the ratio of
myosin isozyme activity in favor of v and this may in turn help to
1
explain the increased rate of contractility in these groups (Davidoff
and Rodgers; Appendix A).

The effects of diabetes and T treatment
3

on ventricular myosin isozyme distribution in SHR and RVH are
presently being investigated in this laboratory.
Several alternative interpretations of the results of this study
could be eliminated by the control studies.

Amelioration of the

cardiodepression and mortality by either insulin or T treatment and
3
by pretreatment with the glucose analog 3-0-methylglucose (Ramanadham
et al. 1987), ruled out the possibility that direct cardiotoxicity of
streptozotocin contributed to the morbidity and mortality of diabetes
in either SHR or RVH.

Neither malnutrition nor reduced heart mass
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alone could account for the observed cardiodepressive effects of
diabetes, since performance was not impaired in either of the food
restricted groups (Davidoff and Rodgers; Appendix A).
Complete glycemic control was not necessary to preserve cardiac
function with diabetes.

Treatment with either lente insulin or

protamine zinc insulin (PZI) effectively maintained cardiac pump
function and SR Ca 2+ uptake, without normalizing serum glucose values
of diabetic SHR (Davidoff and Rodgers; Davidoff et al.).

Rubinstein

et al. (1984) and Rodrigues et al. (1989) reported similar
cardiovascular benefits from graded insulin treatment of normotensive
diabetic rats, without complete normalization of blood glucose.
Lopaschuk et al. (1983) restored SR Ca

2+

uptake in diabetic Wistars

with PZI treatment but did not completely restore blood glucose
concentrations to normal levels.

Strict glycemic control in humans

also does not appear to be necessary for the prevention of diabetic
nephropathies (Dodson and Horton 1988).

T replacement therapy in
3

the diabetic SHR and RVH did not adequately control the hyperglycemia
or hypoinsulinemia, yet effectively restored cardiac function
(Davidoff and Rodgers; Davidoff et al.; Appendix A).

T3 treatment

failed to reverse the weight loss incurred by diabetes while in
general insulin · treatment only partially restored body and heart
weights.
The ability of T to restore SAP of diabetic SHR as effectively
3
as insulin did suggests strongly that hypothyroidism contributes to
the depressor effect of diabetes in this model.

The results of

earlier studies also indicated that thyroid hormone is an important
regulator of arterial pressure in SHR.

-132-

Thyroidectomy of young SHR

prevents the development of hypertension in these animals (Rioux and
Berkowitz 1977; Rodgers and McNeill 1986).

Increased total

peripheral resistance (TPR) is the primary factor contributing to SHR
hypertension (Pfeffer and Frohlich 1973).

Thus, the decline in SAP

of diabetic SHR may be associated with a fall in TPR.

Results

reported by Yamamoto and Nakai (1988) seem to show that moderate
diabetes reduces TPR (estimated by their cardiac index and mean
arterial pressure values) of SHR by about 10-20%, depending on the
duration of diabetes.

Alternatively, the depressor effect of

diabetes on SHR may be primarily cardiogenic.

As mentioned earlier,

T3 treatment restored cardiac function ex vivo to near normal in
diabetic SHR.

Tsujimoto and Hashimoto (1986) attributed most of the

rise in SAP of T3-induced hyperthyroid rats to the cardiac, rather
than the vascular, effects of T . Some of the in vivo hernodynamic
3
effects of diabetes in SHR do not occur in RVH (Appendix A).
Diabetes does not produce a reduction in SAP in RVH, but it does
depress cardiac function.

These observations lend additional support

to suggest that there are direct myocardial effects of diabetes and
the attendant hypothyroidism that are independent of hemodynarnic
changes in vivo.
Treatment with T , like insulin, corrects the bradycardia of
3
diabetic SHR. The bradycardia associated with either diabetes or
hypothyroidism has been attributed, at least in part, to depressed
myocardial responsiveness to adrenergic stimulation (Bilezikian and
Loeb 1983; Gotzsche 1986).

Both hypertrophic (Limas and Limas 1987)

and diabetic (Heyliger et al. 1982; Kashiwagi et al. 1989) myocardium
have been shown to possess a lower density of functional
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6-adrenoceptors.

Both insulin and T may be involved in the
3

regulation of cardiac B-adrenoceptor density (Hawthorn et al. 1988).
Insulin may act indirectly, and possibly completely, by restoring
serum T3 levels (Davidoff and Rodgers; Davidoff et al.; Appendix A).
Depressed myocardial a-adrenoceptor numbers of diabetic SD rats are
restored to normal with either insulin or T treatment, while those
4
of thyroidectomized diabetic rats are not affected by insulin
treatment alone (Sundaresan et al. 1984).

The chronotropic action of

T in vivo may also involve a direct effect of the hormone on
3
pacemaker cells (Kessler-Icekson 1988). The available evidence
implies that perhaps all of the bradycardia associated with
experimental diabetes, in the presence or absence of hypertension,
can be attributed to the attendant hypothyroidism.
In conclusion, the results presented herein show that diabetes
impairs cardiac function to a greater extent in the SHR and the RVH
rat than in the normotensive WKY rat.

Diabetes depresses LV function

(contraction and relaxation) in these hypertensive rats without
dramatically affecting function in normotensive strains (Rodgers
1986; Rodrigues and HcNeill 1986; Davidoff and Rodgers; Davidoff et
al. l.

Reduced rates of Ca 2+ uptake by the SR (Davidoff et al.) from

diabetic SHR hearts probably contribute to these mechanical deficits.
The effects of diabetes on the LV AP are not consistent with those on
performance, since AP configuration is altered comparably in both SHR
and WKY papillary muscles.

It appears that in hypertensive rats

intracellular events subsequent to the cardiac AP are more
susceptible to the adverse effects of diabetes than in normotensive
rats.
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The results of this study also show that the cardiac impairments
associated with diabetes in either the SHR or RVH can be prevented by
T treatment. This is the first known account of a moderate dose of
3
T3 successfully restoring cardiac function, including electrical,
biochemical and mechanical events, in experimental diabetes.

In

addition, T3 treatment, like insulin, prevents the fall in arterial
pressure and bradycardia induced by diabetes in the SHR in vivo, and
either reduces or delays mortality.

The results suggest that

attendant hypothyroidism may play a more significant role in the
development of diabetic cardiomyopathy in the presence of LV
hypertrophy than it does in nonhypertrophic muscle.
Diabetes mellitus is a heterogeneous disease and is
subclassified by the National Diabetes Data Group as either one of
the following:

Type I (insulin-dependent diabetes mellitus or !DOM);

Type II (non-insulin dependent diabetes mellitus or NIDDM);
gestational diabetes; impaired glucose tolerance; or secondary
diabetes.

These results may have some clinical applicability

particularly for IDDM patients.

Hypertension apparently occurs more

frequently among diabetic patients than in the general population
(Fuller 1985; Sprafka et al. 1988; Bell 1989).

It is often regarded

as an important risk factor for the higher cardiovascular morbidity
and mortality in this group (Kannel et al. 1974; Fuller 1985; Sprafka
et al. 1988; Bell 1989).

The incidence of impaired thyroid function

among diabetics may be as high as 30\, is most severe during poor
metabolic control, and is most evident in IDDH (Bagchi 1982).

While

diabetic patients with hypothyroidism may be at increased risk of
cardiovascular morbidity and mortality (Whittingham et al. 1971),
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this risk may be further intensified by hypertension.

Supplemental

thyroid hormone treatment in conjunction with insulin administration
might provide additional therapeutic cardiovascular benefits, in
patients with poorly controlled insulin-dependent diabetes
complicated by attending hypertension and hypothyroidism.

Future studies designed to provide additional information about
the adverse effects of diabetes on hypertrophic myocardium and the
mechanisms by which the attending hypothyroidism influence this
dysfunction may include:
Cellular mechanisms involved in the development of diabetic
cardiomyopathy in the hypertrophic heart can be further characterized
by studying, for example, ventricular myosin isozyme distributions,
individual ionic currents in voltage-clamped isolated myocytes, and
specific enzyme activities associated with sarcolemmal, mitochondrial
and SR membranes.

There are other experimental animal models that

could be used to extend our knowledge about the adverse effects of
diabetes on hypertrophic heart function (including mechanical,
biochemical and electrophysiological indices of function).

A few of

these alternative models are described below.
Hyperlipidemia is another prominent cardiovascular risk factor
in diabetic patients with hypertension (Tzagournis 1989).
Abnormalities in lipid metabolism may account for depressed cardiac
function in SHR and perhaps in RVH.

Diabetes induces hyperlipidemia

in serum of SHR without affecting serum lipid values of WKY rats
(Rodrigues and McNeill 1986).

Cardiac function, serum lipid

profiles, as well as phospholipid content could be assessed in
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diabetic hypertensive rats treated with lipolytic agents.
Antihypertensive therapy in diabetic patients and in diabetic SHR
also reduces the accumulation of some plasma lipids which may account
for improved cardiac performance (Tzagournis 1989j Rodrigues et al.
1986).

The cardiodepressive effects of diabetes may not be as severe in
the SHR in the absence of preexisting hypertrophy.

Antihypertensive

treatment of SHR can reverse or prevent LV hypertrophy (Sen 1983).
The cardiovascular effects of diabetes in nonhypertrophic SHR hearts
could be studied by pretreating SHR with antihypertensive agents
(Ruskoaho 1984).

Chronic diabetes coupled with developing

hypertension and LV hypertrophy may have different effects on cardiac
function than when diabetes is superimposed on preexisting LV
hypertrophy.

Injection of streptozotocin in neonatal SHR causes

diabetes mellitus without interfering with the onset of hypertension
(Iwase et al. 1987a and 1987b).

Simultaneous induction of diabetes

and renovascular hypertension may be an alternative approach.

Since

hypertension often coincides with, but may not precede, diabetes, the
use these experimental models could provide additional information
about the cardiovascular manifestations characteristic of clinical
diabetes.
Hyperglycemia is a predominant metabolic disturbance of diabetes
which results in an increase in intracellular glucose concentration
in tissues where glucose uptake is insulin independent (e.g., liver,
brain and kidney).

In the presence of too much intracellular

glucose, aldose reductase metabolizes glucose, ultimately forming
copious amounts of sorbitol which promotes hypertonicity.
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Clinicians

are presently investigating the therapeutic benefits of aldose
reductase inhibitors (e.g., tolrestat and sorbinil) in order to
minimize the accumulation of the toxic glucose metabolites (see
Swonger and Matejski 1988).

Diabetes reduces glucose transport into

cardiac tissue (Segal 1989), therefore, treatment with an aldose
reductase inhibitor would most likely not have direct beneficial
effects on cardiac function.

However, these drugs may provide

additional indirect protection to the cardiovascular system during
poorly controlled diabetes by improving heptatic, renal and neural
functions.
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APPENDIX A:

cardiac Performance of Diabetic RVH Rats
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SUMMARY
Diabetes markedly depresses cardiac function in the
spontaneously hypertensive rat (SHR).

A low thyroid state appears to

contribute to the impaired mechanical function of diabetic SHR
hearts.

In order to determine whether cardiac dysfunction is

specific for the diabetic SHR, cardiac performance was assessed in
diabetic renovascular hypertensive (RVH) rats.

The 2-kidney, 1-clip

procedure was used to produce hypertension in 11 week-old Wistar
Kyoto (WKY) rats.

Four weeks after surgery, chronic diabetes was

chemically-induced by a single tail vein injection of streptozotocin

A subgroup of diabetic RVH were treated with either

(50 mg/kg).

protamine zinc insulin (I; 10 U/kg/day) or triiodothyronine (T ; 8-10
3

µg/kg/day).

Other control groups included; nondiabetic RVH treated

with same T dose as the diabetic group, food-restricted nondiabetic
3

RVH, and diabetic and nondiabetic normotensive WKY rats.

Weekly in

vivo systolic arterial pressure (SAP) and heart rate (HR) were
recorded throughout the study.

The type of data collected and the

manner in which it was analyzed was similar to the data presented in
Davidoff and Rodgers.

In brief, 8 weeks after the induction of

diabetes animals were sacrificed, serum samples were collected and
mechanical performance of isolated working hearts were assessed.
Following the acquisition of cardiac performance data, wet heart
weights, including whole heart (HW), left ventricular (LV) and right
ventricular (RV) weights, were recorded.

Hypertension in RVH was

characterized by elevated SAP and HR when compared to WKY.

Diabetes

depressed HR only in RVH rat but had no effect on SAP in either RVH
or WKY.

Either insulin or T treatment prevented the drop in HR in
3
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diabetic RVH.

Diabetes impaired LV pressure generation and rates of

contraction and relaxation in RVH but it had no effect on these
measurements in WKY.

T treatment was as effective as insulin was in
3
preventing cardiac depression in diabetic RVH with one exception:

The rate of LV pressure generation was significantly ' higher in
T3-treated diabetic RVH than it was in untreated diabetic RVH, but
the rate of LV pressure generation was also significantly lower in
T -treated diabetic RVH than it was in nondiabetic RVH.
3

The cardiac

performance in nondiabetic RVH was similar to nondiabetic WKY.

The

results provide additional evidence that hypertrophy, induced by 12
weeks of RVH does not adversely affect mechanical function in the
isolated working heart.

Diabetes impairs cardiac function the the

hypertensive, hypertrophic RVH but it does not affect function in the
nonhypertensive, nonhypertrophic WKY.

Hypertrophy may predispose the

myocardium to the adverse effects of diabetes.

Furthermore, the

attendant hypothyroidism may contribute to the functional deficits
characteristic of the diabetic hypertrophic heart.
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Table 1.

Serum glucose, insulin, triiodothyronine and thyroxine levels of
nondiabetic and diabetic RVH and WKY rats.

Group

Nondiabetic

n

11

Glucose
(mg/dl)

127

Insulin
(J.IU/ml)

.t 20

77

44 *

*
10 !. 8

Diabetic

9

500 !.

Diabetic + T3
Diabetic + I

7

693

.t 150 **

8

176

±. 76

273

5

168

.t 33

5

172 +

Nondiabetic + T
3
Nondiabetic FR

Nondiabetic
Diabetic

13
9

140

.t 56
12 *

T

( ng}dll

72

.t

13

38 !. 10

1

*

5.09

.t 1. 44

2.98 !. 1.02 *
tt

116

± 76

0.42

± 0.41

±. 86

86

±. 12

5.36

±. 1.38

84

± 25

397

± 258*

0.33

± 0.10 **

22

36

.t

74

.t

13

3.63

± 1.04 *

±. 40

74

±. 22

87

±.

12

5.19

±. 1.05

26

499 !. 103 *

.t

18 !.

8*

9*

39 ±.13 *

2.35 !,.0.78 *

Values areans ±. SD, obtained 8 weeks after initiation of diabetes or treatment.
T , triiodothyronine; T , thyroxine; I, insulin; FR, food restricted.
3
4
Significantly different from the nondiabetic group (within group).
tt

1

Significantly different from the nondiabetic and diabetic groups.
Significantly different from the nondiabetic WKY.
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TABLE 2.

Body and heart weights of nondiabetic and diabetic RVH and WXY rats.

Group

n

BW

HW
(mg)

(g)

1

LV/BW

LV/RV

(mq/g)

(mg/mg)

1

1556 ± 195

t

1219 !.. 88 * 3.57 !.. 0.35

3.77 i 0.57

y

5.07 ± 0.62

y

11

329 ± 53

Diabetic

9

266 !.. 27

Diabetic + T3
Diabetic + I

7

225 ± 50 *

1258 ± 209 * 4.48 i 0.52 * 4.92 i 0.90

8

356 ±. 48

1508 ±. 125

3.44 ±. 0.55

5.17 ±. 0.63

5

353 ± 24

1628 ± 146

3.59 i 0.46

4.52 ± 0.86 *

5

294 ± 38

1182 ± 59 * 3.29 i 0.48

5.27 i 0.48

13

376 ±. 28

1428 ±. 182

2.92 ±. 0.15

4.57 ±. 0.76

290 !.. 34 *

1070 ±. 75 * 2.91 ±. 0.22

4.58 ±. 0.24

Nondiabetic

Nondiabetic + T
3
Nondiabetic FR

Nondiabetic
Diabetic

9

5.02 !.. 0.39

Values areans ±. SD, obtained 8 weeks after initiation of diabetes or treatment.

r 3 , triiodothyronine; I, insulin; FR, food restricted .

*
y

Significantly different from nondiabetic group (within group).
Significantly different from the nondiabetic WXY.
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TABLE 3.

Systolic arterial pressure (SAP) of nondiabetic and diabetic RVH and

WKY rats.
SAP (mmHgJ
Group

Nondiabetic

n

Week 0

11

136 ±.

3

Week 4

Week 12

201 + 6y

219 ±. lOY

Diabetic

9

126 ±. 4

194 ±. 12

191 ±. 14

Diabetic + T 3
Diabetic + I

7

127 ±. 4

194

6

243 ±. 8

8

126 ±.

4

204 ±. 6

196 ±. 7

Nondiabetic + T3
Nondiabetic FR

s
s

126 ±. 10

194 + 9

215 .±. 12

118 ±. 4

191 ±. 6

203 ±. 18

Nondiabetic
Diabetic

t

13

131

±. 4

133 ±. 3

140 ±.

3

9

144

±.

123 ±.

140 ±.

7

3

4

Values are means±. SE, obtained before renovascular constriction (week 0), 4
weeks after surgery and just before induction of diabetes (week 4), and 8 weeks
after initiation of diabetes or treatment (week 12).
insulin; FR, food restricted.
Y Significantly different from the nondiabetic WKY.
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T3, triiodothyronine; I,

TABLE 4.

Heart rate (HR) or nondiabetic and diabetic RVH and WKY rats.
HR (beats/min)
Week 0

Week 4

Week 12

11

312 .! 13

381 .! 20

364 .! 15l

Diabetic

9

339 .! 16

382 .! 22

310 .! 14

Diabetic + Tl

7

295 .!

5

366 .! 26

386 .! 20

Diabetic + I

8

313 .t 8

364 .t 22

325 .t 19

Nondiabetic + Tl

5

297 .!

6

358 .! 20

324 .!

Nondiabetic FR

5

302 .!

5

386 .! 25

310 .! 34

l30 .t 19

316 .t 7

304 .t 9

285 .t

311 .t

282 ±.

Group

Nondiabetic

Nondiabetic
Diabetic

n

13
9

8

7

•

8

•

7

Values are means ±.SB, obtained before renovascular constriction (week 0), 4
weeks after surgery and just before induction of diabetes (week 4), and 8 weeks
after initiation of diabetes or treatment (week 12).

T3, triiodothyronine; I,

insulin; FR, food restricted.
•Significantly different from nondiabetic group (within group).
l

Significantly different from the nondiabetic WKY.
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Table 5.

LVPP stroke work, left ventricular contractility (LV+dP/dt) and
relaxation (LV-dP/dt) of nondiabetic and diabetic RVH and WXY hearts.

Group

Nondiabetic

n

11

LVPP
(kPa)

Stroke Work

22.38 ±. 1.91

2.44 ±. 0.34

991 ±. 139

(mJ/g)

LV+dP/dt
(kPa/sec)

LV-dP/dt
(kPa/sec)

666 ±. 108
t

Diabetic

9

17.72 ± 2.29 1 1.90 ± 0.43

651 ± 110

Diabetic + T
3
Diabetic + I

7

21.51 ± 3.34

2.23 ± 0.72

810 ±. 154

8

24.86 ±. 2.13

2.33 ±. 0.54

914 ±. 81

726 ±. 128

5

24.76 .± 2.38

2.32 .± 0.53

1029 .± 130

741 ±. 96

5

23.23 ±. 1.87

2.25 ±. 0.37

902 ±. 72

689 ±. 108

13

20.40 ±. 2.74

2.30 ±. 0.59

884 ±. 114

582 ±. 130

9

17.93 ±. 1.88

2.25 ±. 0.69

638 ±. 90

547 ±. 115

Nondiabetic + T
3
Nondiabetic FR

Nondiabetic
Diabetic

tt

529 + 99

t

645 ±. 112

Values are means ±. SO, obtained 8 weeks after initiation of treatment or
Left atrial filling pressure was fixed at 20 cm H o and resistance
2
3
to aortic ejection was fixed at 1.54 kPa/cm /min. Same values are also

diabetes.

represented in Figures 1 and 3.

LVPP, left ventricular pulse pressure; T3,
triiodothyronine; I, insulin; FR, food restricted.
t

tt

Significantly different from nondiabetic group (within group).
Significantly different from nondiabetic and diabetic groups (within group).
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TABLE 6.

Myocardial oxygen consumption

cvo 2 J, cardiac output (CO), power and

efficiency of contraction (El of nondiabetic and diabetic RVH and
WKY.

Group

(c11

f/sec/g)
O

Power
(mW/g)

11

5.06 ±. 1. 04

0.48 ±. 0.07

9.99 ±. 2.01

2.00 ±. 0.31

Diabetic

9

4.09 ±. 1. 34

0.46 ±. 0.09

7.72 ±. 2.22

1.92 ±. 0. 54

Diabetic + r 3
Diabetic + I

7

5.30 ±. 1. 31

0.47 ±. 0 .10

9.93 ±. 3.11

1.84 !,0.24

8

4.83 ±. 1.38

0.42 ±. 0.08

9.78 ±. 2.62

2.06 ±. 0.33

Nondiabetic + T
3
Nondiabetic FR

5

5.00 !. 0.85

0.40 i 0.06

8.85 !. 2.15

1. 76 !. 0.26

5

4. 41 ±. 1.09

0.44 ±. 0.07

9.87 ±. 1.64

2.30 ±. 0.47

13

4.98 ±. 0.94

0.48 ±. 0.07

9.19 ±. 2.04

1.86 ±. 0.36

9

4.96 ±. 1.02

0.56 ±. 0.14

9.71 i 3.45

1.97 ±. 0.57

Nondiabetic

Nondiabetic
Diabetic

Values are means ±. SD, obtained 8 weeks after initiation of treatment or
Left atrial filling pressure was fixed at 15 cm H o and resistance
2
3
to aortic ejection was fixed at 1.54 kPa/cm /min. T , triiodothyronine; I,
3
insulin; FR, food restricted.

diabetes.
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TABLE 7.

Coronary flow rate (CFR) and coronary vascular resistance (CVR) of
nondiabetic and and diabetic RVH and WKY.

Group

n

Nondiabetic
Diabetic
Diabetic

T
3
Diabetic t I
t

Nondiabetic

t

T
3

Nondlabetic FR

Nondiabetic
Diabetic

J

(cm /sec)

CFR

J

c~

(cm /sec/g)

(kPa/cm /sec/g)

0.29 .± 0.07

70.55 .± 5.46

0.26 ±. 0.08

62.92 ±. 4. 67

1

11

0.45 .± 0.13

9

0.31 ±. 0 .10

7

0.37 !,0.11

0.30 ±. 0.08

65.64 ±. 8.83

8

0.40 ±. 0.12

0.27 ±. 0.08

72.64 ±. 3.68

5

0.42 .± 0.10

0.26 ±. 0.05

79.19 .± 5.56

5

0.28 ±. 0.09

0.24 ±. 0.08

97.02 ±. 7 .31*

13

0.44 ±. 0.08

0.31 ±. 0.05

59.70 ±. 4.32

9

0.40 ±. 0.10

0.38 ±. 0.11

45.05 ±. 2.65*

t

t

CFR values are means ±. SD and CVR values are means ±. SE, obtained 8 veeks after
initiation of diabetes or treatment.

CFR was measured when left atrial filling

pressure was fixed at 15 cm H o and resistance to aortic ejection was fixed at
2
3
1.54 kPa/cm /min. CVR (normalized for wet heart weight), when hearts were
pressure loaded.

T , trliodothyronine; I, insulin; FR, food restricted.
3
*Significantly different from nondiabetic group (within group).
1 Significantly different from the nondiabetlc WKY.
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FIGURE 1.

Cardiac performance ex vivo as measured by left

ventricular pulse pressure (LVPP) of nondiabetic (0), diabetic (I),
T -treated diabetic (•) and insulin-treated diabetic (•), T treated
3
3
nondiabetic (A) RVH. The hearts were pressure loaded by varying the
resistance to aortic ejection between 0.19 and 3.13 kPa/cm 3 .min- 1 .
Left atrial filling pressure was fixed at 15 cm H2o.
animals in each group is shown in parenthesis.

The number of

Values are means +

SD, obtained 8 weeks after initiation of diabetes or treatment.

*Significantly

different from the nondiabetic group.
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4

FIGURE 2.

Left ventricular pressure (LVP) waves from perfused

working hearts of nondiabetic, diabetic, insulin-treated diabetic and
T -treated diabetic RVH, under increasing pressure-loading
3
conditions. Each of the four superimposed LVP waves .was obtained at
one of four resistances to aortic ejection:
3

3.13 kPa/cm .min

-1

.

0.19, 0.41, 1.54 and

Left atrial filling pressure was fixed at 15 cm

H o. LVP waves were recorded from a single heart in each group and
2
were obtained eight weeks after initiation of diabetes or treatment.
Analog signals were digitized and stored on a diskette and
regenerated using an IBM PC II with ASYST software and an HP7470
plotter.

Individual records were selected with the aim of

approximating, as closely as possible, the mean maximum LVP values
for each group as shown in Figure 1.
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(msec)

90

APPENDIX B:

Data Acquisition Programs
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\ TRIG. GER
\ The following program allows data acquisition to be
\
sampled from channel #1 when the external trigger
\
button on the Narcotrace recorder is pressed.

DT2800
INTEGER SCALAR T.RATE
20 T.RATE .INTEGER DIM[ 250 l ARRAY DATA.BUF.l INTEGER DIM[ 250 l ARRAY
DATA.BUF.2
1 1 AID.TEMPLATE CHNL.l.IN
DATA.BUF.l DATA.BUF.2 CYCLIC DOUBLE.TEMPLATE.BUFFERS
START.ACQ
CHNL.l.IN AID.INIT
3 AID.GAIN A/D.INIT
CLEAR.TASKS
1 TASK A/D.IN>ARRAY
T.RATE TASK.PERIOD
PRIME.TASKS
TRIGGER . TASKS ;

\ Starts data acquisition,
\ input on channel 1

STOP.ACQ
STOP.TASKS
CLEAR.TASKS ;

\ Stops data acquisition

PLOT. IT
\ Plots data continually until
BEGIN
\ a key is pressed. This is
ERASE . LINES
\ used for checking calibration
BEGIN ?BUFFER.SWITCH UNTIL
\ of machines
?BUFFER.AIB
IF DATA.BUF.l ELSE DATA.BUF.2
THEN 2 217 AID.SCALE Y.DATA.PLOT
?KEY UNTIL ;
. REAL DIM[ 5000

ARRAY PIXBUF

SET.GRAPHICS
\ Sets graphics display for
GRAPHICS.DISPLAY
\ checking calibration
AXIS.FIT.OFF
HORIZONTAL O. 250. WORLD.SET
VERTICAL
0. 150. WORLD.SET
OUTLINE
XY.AXIS.PLOT
PIXBUF LINE.BUFFER.ON
SET.GRAPHS
\ Sets graphics display for
GRAPHICS.DISPLAY
\ acquired data points
AXIS.FIT.OFF
HORIZONTAL 0. 1000. WORLD.SET
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AXIS.FIT.OFF
VERTICAL
0. 250. WORLD.SET
OUTLINE
XY.AXIS.PLOT
\ Show axis and grid lines
PIXBUF LINE.BUFFER.ON
CHECK. IT
SET.GRAPHICS
START.ACQ
PLOT. IT
STOP.ACQ ;

\ Allows continual monitoring
\ of input for checking
\ calibration
\DOES NOT STORE DATA!!!!!

1 1 aid . template 5PP EXT.TRIG AID.INIT
integer dim[ 1000 1 array BEAT
BEAT template.buffer A/D.INIT \ Defines the input channel tl
2. conversion.delay ald.init \ to be activated by an external
INTEGER SCALAR COUNT
\ trigger signal. Sets array size 0
COUNT .\ (how many data points to be
\ collected and stored)
YUP 5PP EXT.TRIG AID.INIT
3 AID.GAIN A/D.INIT
\ Waits for external trigger to
STACK.CLEAR
\ be pressed before acquiring data
BEG.IN BELL AID.IN>ARRAY
\ BELL rings before data is
?BUFFER.FULL
\ collected then another BELL after
UNTIL
BELL
\ data collection is complete
COUNT SUBFILE BEAT ARRAY>FILE
COUNT . ,
GRAPHS
BEAT 2 217 AID.SCALE
Y. DATA . PLOT ;
14

\ Graphs acquired data

STRING FILENAME
CREATE.DATA.FILE
\ Creates a file on a disk (be
FILE.TEMPLATE
\ sure to specify B:FILENAME)
\ 15 subfiles are available,
15 COMMENTS
BEAT []FORM.SUBFILE
\ therefore, 15 separate arrays
15 TIMES
\ can be acquired and stored
END
CR ." NAME OF FILE TO CREATE? "
"INPUT FILENAME ":=
FILENAME DEFER> FILE.CREATE
FILE.OPEN ;
RESTART. IT
BEGIN
COUNT 1 + COUNT :=
YUP
ERASE.LINES
GRAPHS
?KEY UNTIL ;

\
\
\
\

Adds sequential numbers to number
stack so that subsequent data
points (arrays) are put in
consecutive subfiles
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CLEAN.UP
LINE.BUFFER.OFF
AXIS. DEFAULTS
SCREEN.CLEAR
CR ." Data acquisition finished"
CR
BELL ;
END.DATA.ACQ
FILE.CLOSE
0 COUNT :=
CLEAN.UP ;
F9 FUNCTION.KEY.DOES END.DATA.ACQ
GO.TEAM
CREATE.DATA.FILE
SET.GRAPHS
RESTART.IT ;

\ Initiates program to create
\ a data file and collect data

\ To check machine calibration, type "CHECK.IT (return)".
\To initiate the program to store data, type "GO.TEAM (return)".
\ To end data acquisition and close data file, press
\
F9 and HIT the external trigger one more time.
\
"OH BOY!"
BELL BELL
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\
\
\
\
\
\

EXT.TRG
This program allows user to monitor and store
electrophysiological data from channel #2
(e.g., cardiac action potentials)
Data acquisition is controlled by an external trigger signal
or continually monitored for calibration

DT2800
INSTRUCTIONS
CR " <F3>
CR " <F5>
CR II <F7>
CR " <F9>

End data acquisition
Create a data file
Change sensitivity
View potentials

<F4>
<FG>
<F8>
<FlO>

Continual display
Instructions
Set graphics
Add to data file

REAL SCALAR DEFAULT.NUMBER
SENSITIVITY
CR ." Select sensitivity,
.125 DEFAULT.NUMBER :=
#INPUT
IF
DEFAULT.NUMBER .THEN
INSTRUCTIONS ;
REAL DIM( 5000

e.g., .2 or .5 (else .125) "
\ Asks user for the desired
\ sensitivity, default value
\ was good for AJD (8/89)

ARRAY PIXBUF

SET.GRAPHICS
\ Set axes to plot acquired
\ data points (arrays)
VUPORT.CLEAR
0. 200.
HORIZONTAL WORLD.SET
WORLD.SET
-.125 .025 VERTICAL
XY.AXIS.PLOT
PIXBUF LINE.BUFFER.ON
2 2 A/D.TEMPLATE CHNL2 EXT.TRIG
INTEGER DIM[ 200 l ARRAY APS
APS TEMPLATE.BUFFER

\ Define input channel #2
\ controlled by external
\ trigger signal

INTEGER SCALAR COUNT
0 COUNT :=
14

STRING FILENAME
\ Create a data file to store
CREATE.DATA.FILE
\ acquired data points
FILE.TEMPLATE
APS []FORM.SUBFILE
\ Prompts user for file name
30 TIMES
\ BE SURE to specify B:FILENAME!
\ Allows 30 ARRAYS to be collected
END
CR . " Name of file to create? "
"INPUT FILENAME ":=
FILENAME DEFER> FILE.CREATE
FILE.OPEN ;
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"
"
"
"

CLEAN.UP
\ Resets default values
LINE.BUFFER.OFF
AXIS.DEFAULTS
SCREEN.CLEAR
VUPORT.CLEAR
CR ." Data acquisition finished, YEAH!? "
CR
BELL ;
END.DATA.ACQ
FILE.CLOSE
0 COUNT :=
CLEAN.UP ;

\ Ends data acquisition,
\ closes file and resP.ts
\ count to equal 0

START. AGAIN
CHNL2
3 AID.GAIN AID.INIT
BEGIN
AID.IN>ARRAY
?BUFFER.FULL
UNTIL
BELL ;

\ Initiates data collection
\ BELL rings when complete

GRAPH. IT
APS DEFAULT.NUMBER -1 *
DEFAULT.NUMBER AID.SCALE
Y.DATA.PLOT;

\ Scales and plots acquired data

\ DOES NOT STORE DATA!

ADD.TO.DATAFILE
\ Collects, STORES and graphs data
COUNT 1 t COUNT .START.AGAIN
COUNT SUBFILE APS ARRAY>FILE BELL
COUNT
GRAPH.IT ;
VIEW. IT
START .AGAIN
GRAPH. IT ;

\ Collects data (without storing)
\ and graphs it

GET. IT
SUBFILE APS FILE>ARRAY
APS DEFAULT.NUMBER -1 *
DEFAULT.NUMBER AID.SCALE
Y.DATA.PLOT ;

\
\
\
\

Used to check stored data
Put number on number stack
(type a number and return)
then GET. IT

\
\
\
\

Defines channel t2 as cyclical APS.l
in order to continually plot
BUT NOT STORE data
Use to check calibration

INTEGER DIM( 200 l ARRAY APS.l
2 2 AID.TEMPLATE CHNLl
CYCLIC TEMPLATE.BUFFER
INTEGER SCALAR T.RATE
2. T.RATE .SET.UP
CHNLl
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3 AID.GAIN AID.INIT
CLEAR.TASKS
1 TASK AID.IN>ARRAY
T.RATE TASK.PERIOD
PRIME.TASKS
TRIGGER.TASKS
START.ACQ
\ Starts data acquisition
BEGIN
\ continually plots input
ERASE.LINES
\ data until a key is pressed
BEGIN ?BUFFER.SWITCH UNTIL
APS.l DEFAULT.NUMBER -1 *
DEFAULT.NUMBER AID.SCALE
Y.DATA.PLOT
?KEY UNTIL BELL ;
STOP.ACQ
STOP.TASKS
CLEAR.TASKS

\ Stops data acquisition

CONTINUOUS
SET.UP
START.ACQ
STOP.ACQ
CLEAR. TASKS

\ Initiates program to continually
\ monitor input, WITHOUT storing
\ the data

20 0 24 79 WINDOW {BOT}
GO.TEAM
CREATE.DATA.FILE
SENSITIVITY
DEFAULT.NUMBER
GRAPHICS.DISPLAY
SCREEN.CLEAR
{BOT}
0 .20 VUPORT.ORIG
1 .80 VUPORT.SIZE
INSTRUCTIONS ;
F3
F4
F5
F6
F7
F8
F9
FlO

FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES

\ Defines vuport space for
\ instructions
\
\
\
\

Initiates program to create a
data file, set sensitivity, set
graphics display, present
instructions

\ Save bottom four lines
\ for text
END.DATA.ACQ
CONTINUOUS
CREATE.DATA.FILE
INSTRUCTIONS
SENSITIVITY
SET.GRAPHICS
VIEW.IT
ADD.TO.DATAFILE

BELL BELL
\To initiate program, type "GO.TEAM (return)".
\ If you are not sure what to do, type "INSTRUCTIONS (return)"
\ at any time to refresh instruction screen
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\
\
\
\
\
\
\
\

If you ever want to overwrite collected data, type "t COUNT :=
(return)". Specify the number (#) corresponding to the subfile
PRIOR TO the one you want to write over (e.g., 3 COUNT := will
set count to 3, when EXT TRIG is pressed, data will be stored
in subfile #4
To end data acquisition and close file press (F3)
Program allows for 30 arrays to be stored
GOOD LUCK MR/MS PHELPS!
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\ ANALYZE.LVP
\
\
\
\

Program allows user to look at stored data points (arrays)
within a file, plot the arrays, extract a portion (300 msec),
plot subset on HP plotter, and store that subset in a
SEPARATE file

DT2800
LOOK.SEE
\ Sets up axes to view stored
GRAPHICS.DISPLAY
\ LVPs (arrays) in data file
AXIS.DEFAULTS
HORIZONTAL 0 1000 WORLD.SET
VERTICAL 0 180 WORLD.SET
GRAPHICS.READOUT
NORMAL.COORDS
.7 .975 READOUT>POSITION
XY.AXIS.PLOT ;
SUBPLOT.AXES
VUPORT.CLEAR
HORIZONTAL 0 270 WORLD.SET
VERTICAL 0 180 WORLD.SET
XY.AXIS.PLOT

\ Sets up axes to view subsets
\ of LVPs in data file

LABEL.PLOT
NORMAL.COORDS
.5 .05 POSITION
"
TIME (msec) 11 LABEL
90 LABEL.DIR
.025 .4 POSITION
II
LVP ( mmHg) II LABEL
WORLD.COORDS ;

\ Defines coordinates, axes and
\ labels axes on HP plotter

45 STRING ANIMAL
HEADER
\ Asks for title name for the
NORHAL.COORDS
\ graph to be plotted
0 LABEL.DIR
. 4 . 9 5 POSITION
CR . 11 Animal number and group? II
"INPUT ANIMAL 11 :=
ANIMAL LABEL i
HP.PLOTTER
HP7470
PLOTTER.DEFAULTS
SUBPLOT.AXES
LABEL.PLOT
HEADER

\ Plots axes, labels and title

PLOT. IT
Y.DATA.PLOT
STACK.CLEAR i

\ Plot a named array (LVP) either
\ on CRT screen or on HP plotter
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INTEGER DIM( 1000 l ARRAY LVP
GET. IT
SUBFILE LVP FILE>ARRAY
LVP 0 200 AID.SCALE

\
\
\
\

Waits for a number on number
stack (e.g., 1 for subfile 1
which contains FPlS), reads
the array and plots it

SCALAR RANGES
RESCALE.IT
." Range for scaling? "
#INPUT RANGES :=
SUBFILE LVP FILE>ARRAY
LVP 0 RANGES AID.SCALE ;
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER

DIM(
DIM!
DIM(
DIM(
DIM(
DIM[
DIM(
DIM[

300
300
300
300
300
300
300
300

ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY

\ Allows user to rescale raw
\ data stored in files, if
\ calibration was incorrect

FPlS
FP20
FPlO
FPS
RJ
R4
R2
Rl

SCALAR STARTING.PT
DEFINE. IT
CR ." Starting point? "
#INPUT STARTING.PT :=
SUB[ STARTING.PT , 300
CR
" Array Name? "

\ Defines subset of arrays in
\data file (for area analysis)
\ specify starting point (X-axis)
\ Name the subset (e.g., FPlS or
\ R3)

14 STRING FILENAME
INTEGER DIM[ 300 l ARRAY LVPP
CREATE.SUB.FILE
\ Create a file to store the
FILE.TEMPLATE
\ defined subsets
8 COMMENTS
LVPP []FORM.SUBFILE
8 TIMES
END CR ."Name of file to create? "
"INPUT
FILENAME ":=
FILENAME DEFER> FILE.CREATE FILE.OPEN
II FPlS" 1 >COMMENT
" FP20" 2 >COMMENT
II FPlO"
3 >COMMENT
" FPS" 4 >COMMENT
II R3"
s >COMMENT
II R4"
6 >COMMENT
II R2"
7 >COMMENT
" Rl"
8 >COMMENT
BELL ;
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WRITE. IT
1 SUBFILE
2 SUBFILE
3 SUBFILE
4 SUBFILE
5 SUBFILE
6 SUBFILE
7 SUBFILE
8 SUBFILE
BELL ;
F2
F3
F4
F5
F6
F7
F8
F9
FlO

FP15
FP20
FPlO
FPS
R3
R4
R2
Rl

ARRAY> FILE
ARRAY> FILE
ARRAY>FILE
ARRAY> FILE
ARRAY> FILE
ARRAY> FILE
ARRAY>FILE
ARRAY> FILE

FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES

\ Stores defined subsets into
\ newly created file

RESCALE.IT
PLOT.IT
CREATE.SUB.FILE
SUBPLOT.AXES
LOOK.SEE
GET.IT
DEFINE.IT
HP.PLOTTER
WRITE.IT

BELL BELL
\
\
\
\
\
\
\
\
\
\

To initiate program, open data file in drive B:
(FILE.OPEN B:filename).
Plot LOOK.SEE axes (F6), type a number corresponding to desired
subfile, and plot it or GET.IT (F7).
Cursor can be used to determine starting point for subset
(position cursor and press HOME KEY for read out - see ASYST
manual for more detail on cursor movement).
Before creating a new file for the subset arrays, be sure to
close the parent file (FILE.CLOSE), then CREATE.SUB.FILE
(F4).
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\ AREA.PLT
\
\
\
\

Program allows user to call up (GET.IT) stored subfiles,
graph the arrays, and move cursor around to outline LVP wave
(e.g., from Pmax to max EDP), in order to calculate the
area defined

DT2800
COMPLEX SCALAR ZO REAL
SCALAR AREA AXIS.DEFAULTS
NEXT. POINT
SWAP CONJ
OVER *
ZIHAG
2. I

AREA + AREA :=
POINT
?CURSOR
3 PICK
ZRE&IH POSITION
DRAW.TO
?CURSOR
Z=X+IY
NEXT .POINT
FIRST. POINT
?CURSOR
Z=X+IY
DUP ZO :=
0. AREA :=
BELL ;
LAST.POINT
POINT
ZO ZRE&IH DRAW.TO
ZO NEXT.POINT DROP
GRAPHICS.READOUT
CR AREA .
BELL
STACK.CLEAR
SUBPLOT.AXES
GRAPHICS.DISPLAY
HORIZONTAL 0 270 WORLD.SET
VERTICAL 0 180 WORLD.SET
GRAPHICS.READOUT
NORHAL.COORDS
.7 .975 READOUT>POSITION
WORLD.COORDS
XY.AXIS.PLOT
PLOT. IT
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Y.DATA.PLOT
ARRAY.READOUT
INTEGER DIM( 300

ARRAY WAVES

GET.IT
SUBFILE WAVES FILE>ARRAY
WAVES
PLOT.IT
Fl
F2
F3
FS
F7
F8

FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES

\ Reads the subfile specified by
\ the number placed on number stack

FIRST.POINT
POINT
LAST.POINT
SUBPLOT.AXES
GET.IT
PLOT.IT

BELL BELL
\ NOTE: See ASYST manual for more detailed instruction about
cursor movement.
ARROWS on key pad moves cursor.
HOME KEY gives read out of present cursor position.
PG UP changes the increment of cursor movement, e.g., strike
\ once = slowest or smallest distance moved, strike multiple
\ times in succession = larger increments.

\
\
\
\
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\ ANALYZE.APS
\ This program allows user to analyze the area of AP records,
\ AP durations, RMPs, dV/dt's, and plot APs -0n HP plotter
\ Type the word "INSTRUCTIONS" to list function key assignments
DT2800
COMPLEX

SCALAR ZO REAL

SCALAR AREA

NEXT. POINT
SWAP CONJ
OVER *
ZIMAG
2. I

AREA + AREA .POINT
?CURSOR
3 PICK
ZRE&IM POSITION
DRAW. TO
?CURSOR
Z=X+IY
NEXT.POINT
FIRST.POINT
?CURSOR
Z=x+ I Y
DUP ZO
.0. AREA .BELL ;
LAST.POINT
POINT
ZO ZRE&IM DRAW.TO
ZO NEXT.POINT DROP
GRAPHICS.READOUT
CR AREA .
BELL
STACK.CLEAR ;
GRAPHS
VUPORT.CLEAR
AXIS.DEFAULTS
HORIZONTAL 0 200 WORLD.SET
VERTICAL -125 25 WORLD.SET
GRAPHICS.READOUT
NORMAL.COORDS
.7 .975 READOUT>POSITION
XY.AXIS.PLOT ;
LABEL.PLOT
NORMAL.COORDS
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.5 .05 POSITION
"
TIME (msec)" LABEL
90 LABEL. DIR
.025 .4 POSITION
"
MP ( mV)" LABEL
WORLD.COORDS ;
45 STRING ANIMAL
HEADER
NORMAL.COORDS
0 LABEL.DIR
.4 .95 POSITION
CR . " Animal number and group?
"INPUT ANIMAL ":=
ANIMAL LABEL
WORLD.COORDS

"

HP.PLOTTER
HP7470
PLOTTER.DEFAULTS
VUPORT.CLEAR
HORIZONTAL 0 200 WORLD.SET
VERTICAL -125 25 WORLD.SET
XY.AXIS.PLOT
LABEL.PLOT
HEADER ;
INTEGER DIM[ 200 I ARRAY APS INTEGER DIM[ 200 l ARRAY AP
GET. IT
0 AP :=
SUBFILE APS FILE>ARRAY
APS -125 125 AID.SCALE
AP : = ;
.5 SET.CUTOFF.FREQ 1 SET.#.OPTIMA

VMAX
DIFFERENTIATE.DATA
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER

DIM[
DIM[
DIM[
DIM[
DIM[
DIM[
DIM[
DIM[
DIM[
DIM[
DIM[
DIM[

200
200
200
200
200
200
200
200
200
200
200
200

ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY

APl
AP2
AP3
AP4
AP5
AP6
AP?
AP8
AP9
APlO
APll
AP12
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INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER

DIM(
DIM(
DIM(
DIM(
DIM(
DIM(
DIM(
DIM(
DIM(
DIM(
DIM(
DIM(
DIM(
DIM(
DIM(
DIM(
DIM(
DIM(

200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200

ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY
ARRAY

AP13
AP14
AP15
AP16
APl 7
AP18
AP19
AP20
AP21
AP22
AP23
AP24
AP25
AP26
AP27
AP28
AP29
APJO

GET.THEM
1 SUBFILE APl FILE>ARRAY
APl -125 125 AID.SCALE APl .2 SUBFILE AP2 FILE>ARRAY
AP2 -125 125 AID.SCALE AP2 .3 SUBFILE AP3 FILE>ARRAY
AP3 -125 125 AID.SCALE APJ .4 SUBFILE AP4 FILE>ARRAY
AP4 -125 125 AID.SCALE AP4 .5 SUBFILE AP5 FILE>ARRAY
AP5 -125 125 AID.SCALE AP5 .6 SUBFILE AP6 FILE>ARRAY
AP6 -125 125 AID.SCALE AP6 .7 SUBFILE AP7 FILE>ARRAY
AP7 -125 125 AID.SCALE AP7 .8 SUBFILE AP8 FILE>ARRAY
AP8 -125 125 AID.SCALE AP8 .9 SUBFILE AP9 FILE>ARRAY
AP9 -125 125 AID.SCALE AP9 .10 SUBFILE APlO FILE>ARRAY
APlO -125 125 AID.SCALE APlO .11 SUBFILE APll FILE>ARRAY
APll -125 125 AID.SCALE APll .12 SUBFILE AP12 FILE>ARRAY
AP12 -125 125 AID.SCALE AP12 .13 SUBFILE AP13 FILE>ARRAY
AP13 -125 125 AID.SCALE AP13 .14 SUBFILE AP14 FILE>ARRAY
AP14 -125 125 AID.SCALE AP14 .15 SUBFILE AP15 FILE>ARRAY
AP15 -125 125 AID.SCALE AP15 .16 SUBFILE AP16 FILE>ARRAY
AP16 -125 125 AID.SCALE AP16 .17 SUBFILE AP17 FILE>ARRAY
AP17 -125 125 AID.SCALE AP17 .-168-

18 SUBFILE AP18 FILE>ARRAY
AP18 -125 125 AID.SCALE
19 SUBFILE AP19 FILE>ARRAY
AP19 -125 125 AID.SCALE
20 SUBFILE AP20 FILE>ARRAY
AP20 -125 125 AID.SCALE
21 SUBFILE AP21 FILE>ARRAY
AP21 -125 125 AID.SCALE
22 SUBFILE AP22 FILE>ARRAY
AP22 -125 125 AID.SCALE
23 SUBFILE AP23 FILE>ARRAY
AP23 -125 125 AID.SCALE
24 SUBFILE AP24 FILE>ARRAY
AP24 -125 125 AID.SCALE
25 SUBFILE AP25 FILE>ARRAY
AP25 -125 125 AID.SCALE
26 SUBFILE AP26 FILE>ARRAY
AP26 -125 125 AID.SCALE
27 SUBFILE AP27 FILE>ARRAY
AP27 -125 125 AID.SCALE
28 SUBFILE AP28 FILE>ARRAY
AP28 -125 125 AID.SCALE
29 SUBFILE AP29 FILE>ARRAY
AP29 -125 125 AID.SCALE
30 SUBFILE AP30 FILE>ARRAY
AP30 -125 125 AID.SCALE
BELL ;

AP18

.-

AP19

AP22

....-

AP23

:=

AP24

.-

AP25

.-

AP26

...-

AP20
AP21

AP27
AP28
AP29
AP30

.-

INSTRUCTIONS
CR II
CR II <F5> Get one array from file
CR II <F7> Plotter
CR II <F9> Get all arrays from file
PLOT. IT
Y.DATA.PLOT
STACK.CLEAR
LOCATE. IT
LOCAL.MAXIMA
POSITION ;
20 0 24 79 WINDOW {BOT}
GO.TEAM
GRAPHICS.DISPLAY
SCREEN.CLEAR
{BOT}
0 .20 VUPORT.ORIG
1 .80 VUPORT.SIZE
INSTRUCTIONS ;
Fl

FUNCTION.KEY.DOES FIRST.POINT
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<F4>
<F6>
<F8>
<FlO>

Plot array
Vmax for array
Set graphics
Locate Vmax

II

"
II
ff

F2
F3
F4
F5
FG
F7
F8
F9
FlO
\
\

FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES
FUNCTION.KEY.DOES

POINT
LAST.POINT
PLOT.IT
GET.IT
VMAX
HP.PLOTTER
GRAPHS
GET.THEM
LOCATE.IT

Type GO.TEAM to initiate program or to return graphics to
the CRT rather than the plotter

BELL BELL
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